documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registranttable contents gilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences truvada viread emtriva hepsera ambisome vistide letairis volibris atripla registered trademark belonging bristol myers squibb gilead sciences llc macugen registered trademark belonging osi pharmaceuticals inc sustiva registered trademark bristol myers squibb pharma company tamiflu registered trademark belonging hoffmannla roche inc flolan registered trademark smithkline beecham corporation report also includes trademarks service marks trade names companiestable contents annual report including section entitled managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forward looking statements including statements regarding overall trends operating cost trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forwardlooking statements various reasons including identified risk factors beginning given risks uncertainties cautioned place undue reliance forwardlooking statements forward looking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise table contents part item business overview gilead sciences inc gilead us incorporated delaware june biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering life threatening diseases worldwide headquartered foster city california operations north america europe australia date focused efforts bringing novel therapeutics treatment life threatening diseases market continue seek add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy products truvada emtricitabine tenofovir disoproxil fumarate oral formulation dosed day part combination therapy treat human immunodeficiency virus hiv infection adults fixed dose combination antihiv medications viread tenofovir disoproxil fumarate emtriva emtricitabine atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oral formulation dosed day treatment hiv infection adults atripla first daily single tablet regimen hiv intended stand alone therapy combination antiretrovirals fixed dose combination antihiv medications viread emtriva bristol myerssquibb companys nonnucleoside reverse transcriptase inhibitor sustiva efavirenz viread oral formulation nucleotide analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults received marketing approval viread treatment chronic hepatitis b united states european union countries including canada turkey emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also approved part combination therapy treat hiv infection children hepsera adefovir dipivoxil oral formulation nucleotide analogue polymerase inhibitor dosed day treat chronic hepatitis b licensed rights commercialize hepsera treatment hepatitis b asia latin america certain territories glaxosmithkline inc gsk ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species corporate partner astellas pharma inc astellas promotes sells ambisome united states canada promote sell ambisome europe australia new zealand letairis ambrisentan endothelin receptor antagonist era indicated treatment pulmonary arterial hypertension pah group patients class ii iii symptoms improve exercise capacity delay clinical worsening letairis available special restricted distribution program called letairis education access program leap prescribers pharmacies registered leap may prescribe sell distribute letairis sublicensed gsk rights ambrisentan marketed gsk volibris certain hypertensive conditions territories outside united states vistide cidofovir injection antiviral medication treatment cytomegalovirus retinitis patients aids sell vistide united states wholesale channel countries outside united states table contents flolan epoprostenol sodium injected medication longterm intravenous treatment primary pulmonary hypertension pulmonary hypertension associated scleroderma spectrum disease new york heart association class iii class iv patients respond adequately conventional therapy exclusive rights market promote distribute flolan sterile diluent flolan united states april flolan distributed united states specialty pharmacy following table lists aggregate product sales major products thousands total total total product product product sales sales sales antiviral products truvada atripla viread hepsera emtriva total antiviral products ambisome letairis total product sales see item note consolidated financial statements included annual report total revenues geographic area royalties products tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approved treatment influenza children adults countries including united states japan european union also approved prevention influenza children adults united states japan european union developed tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us royalties based percentage net sales tamiflu worldwide macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelated macular degeneration macugen developed osi pharmaceuticals inc osi using technology licensed us promoted united states osi osi holds exclusive rights manufacture sell macugen united states pfizer inc pfizer holds exclusive right manufacture sell macugen rest world receive royalties osi based sales macugen worldwide commercialization distribution us international commercial sales operations marketing subsidiaries australia austria belgium canada denmark finland france germany greece ireland italy netherlands new zealand norway portugal spain sweden switzerland turkey united kingdom united states products marketed commercial teams andor conjunction third party distributors corporate partners commercial teams promote products direct field contact physicians table contents hospitals clinics healthcare providers generally grant third party distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory united states commercial team promotes truvada viread emtriva hepsera letairis flolan promote atripla united states joint venture partner bristol myerssquibb company bms currently distribute truvada atripla viread emtriva hepsera vistide united states exclusively wholesale channel product sales three large wholesalers cardinal health inc mckesson corp amerisourcebergen corp accounted total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total revenues corporate partner astellas promotes sells distributes ambisome us united states two products letairis flolan distributed exclusively specialty pharmacies specialty pharmacies specialize dispensing medications complex chronic conditions may require high level patient education ongoing counseling territories outside united states sell distribute truvada viread emtriva hepsera ambisome asia australia europe latin america middle east new zealand either commercial teams third party distributors promote atripla jointly bms majority countries europe responsible selling distributing product countries limited number central eastern european countries either bms third party distributor sole promoting selling distributing company smaller group noneuropean union eastern central european countries atripla promoted bms either directly third party distributors agreement merck co inc merck plan promote distribute atripla twelve countries latin america asiapacific either merck existing third party distributor partners rely corporate partner japan tobacco inc promote sell truvada viread emtriva japan corporate partner astellas also promotes sells distributes ambisome canada dainippon sumitomo pharma co ltd responsible promotion distribution ambisome japan access developing world gilead access program established certain gileads hiv products available substantially reduced prices countries developing world developed system tiered pricing reflects economic status using gross national incomegniper capita hiv prevalence approach allows us price therapies based countrys ability pay example higher prevalence exists certain country country also relatively high gni country would moved lower price tier accommodate higher burden disease also support many clinical studies donation products help define best treatment strategies developing world countries example november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection clinical study conducted mrc antiretroviral hiv therapy africa trial called dart development antiretroviral therapy study aimed studying clinical versus laboratory monitoring practices structured treatment interruptions continuous antiretroviral therapy adults hiv infection subsaharan africa provide viread cost dart study also work closely world health organization nongovernmental organizations provide ambisome treatment leishmaniasis parasitic disease preferential price resource limited settings support numerous clinical studies investigating role ambisome treat visceral cutaneous leishmaniasis developing countries collaborations organizations drugs neglected diseases initiative mdecins sans frontires table contents also entered number collaborations related access products developing world include pharmachem technologies grand bahama ltd pharmachem technologies established facility bahamas manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients truvada atripla resource limited countries cooperative effort pharmachem technologies grand bahama port authority aspen pharmacare holdings ltd aspen october entered nonexclusive manufacturing distribution agreement aspen providing manufacture distribution viread truvada treatment hiv infection certain developing world countries included gilead access program november amended agreement aspen amended agreement aspen retained right manufacture distribute viread truvada treatment hiv infection certain developing world countries gilead access program aspen right purchase viread truvada britestock form us distribution countries also right manufacture viread truvada using active pharmaceutical ingredient purchased aspen suppliers approved us aspen also granted right manufacture distribute generic versions emtricitabine tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen required pay us royalties net sales viread truvada well royalties net sales generic versions tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination emtricitabine manufactured distributed aspen generic licenses entered nonexclusive license agreements ten indian generic manufacturers granting rights produce distribute generic versions tenofovir disoproxil fumarate treatment hiv infection low income countries around world included india many low income countries gilead access program agreements require generic manufacturers meet certain national international regulatory standards include technology transfer enable expeditious production large volumes high quality generic versions tenofovir disoproxil fumarate addition agreements allow manufacture commercial quantities active pharmaceutical ingredient finished product merck august entered agreement affiliate merck pursuant provide atripla substantially reduced prices hiv infected patients developing countries africa caribbean latin america southeast asia agreement manufacture atripla using efavirenz supplied merck merck handles distribution product countries covered agreement international partnership microbicides ipm conrad december entered agreement granted rights ipm conrad cooperating agency us agency international development usaid committed improving reproductive health expanding contraceptive choices women men develop manufacture proven efficacious arrange distribution resource limited countries tenofovir microbicide prevent hiv infection competition products development programs target number areas including viral fungal respiratory cardiovascular diseases many commercially available products treatment diseases many companies institutions making substantial investments developing additional products treat diseases products compete available products based primarily efficacy safety table contents tolerability acceptance doctors ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv products hiv landscape becoming competitive complex treatment trends continue evolve growing number antihiv drugs currently sold advanced stages clinical development approximately branded hiv drugs available united states products primarily compete fixed dose combination products nucleotidenucleoside reverse transcriptase inhibitors nrti class including combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sold gsk hiv products compete directly products nrti class sold bms although hiv products also compete broadly hiv products abbott laboratories inc boehringer ingelheim gmbh merck pfizer roche tibotec therapeutics division ortho biotech products lp subsidiary johnson johnson bmss videx ec didanosine ddi became first generic hiv product united states gsks retrovir zidovudine also faces generic competition united states result launch generic zidovudine gsks zerit stavudine also faces generic competition united states result launch generic stavudine date little impact generic didanosine zidovudine stavudine price hiv products however price decreases hiv products may result longer term ambisome ambisome faces strong competition several current expected competitors competition current expected competitors may erode revenues receive sales ambisome ambisome faces competition vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere ambisome also competes lipidbased amphotericin b products including abelcet amphotericin b lipid complex injection sold enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sold three rivers pharmaceuticals llc worldwide anfogen amphotericin b liposomal sold genpharma sa argentina bms numerous generic manufacturers sell conventional amphotericin b also competes ambisome aware least two lipid formulations claim similarity ambisome becoming available outside united states including possible entry one formulation greece formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association hbv products hepatitis b virus hbv products hepsera viread face significant competition existing expected therapies treating patients chronic hepatitis b hbv products face competition baraclude entecavir oral nucleoside analogue developed bms launched united states tyzekasebivo telbivudine oral nucleoside analogue developed novartis pharmaceuticals corporation novartis sale united states european union china table contents hbv products also compete epivirhbvzeffix lamivudine developed gsk collaboration shire pharmaceuticals group plc sold major countries throughout north south america europe asia hepsera viread treatment hepatitis b also compete established immunomodulatory therapies including introna interferon alfab sold schering plough corporation major countries throughout north south america europe asia pegasys pegylated interferon alfaa injectable drug similar introna sold roche treatment chronic hepatitis b letairis letairis competes directly tracleer bosentan sold actelion pharmaceuticals us inc indirectly pah products united therapeutics corporation pfizer vistide vistide competes number drugs also treat cytomegalovirus retinitis including cytovene iv cytovene ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valcyte valganciclovir also marketed roche foscavir foscarnet intravenous drug sold astrazeneca plc vitravene fomivirsen drug injected directly eye sold cibavision flolan flolan competes primarily remodulin treprostinil form prostacyclin administered via continuous subcutaneous infusion continuous intravenous infusion sold united therapeutics corporation united states flolan also competes ventavis iloprost inhaled form prostacyclin sold affiliates actelion ltd united states addition patent covering flolan expired one generic pharmaceutical companies may launch generic version flolan united states tamiflu tamiflu competes relenza zanamivir antiinfluenza drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine rimantadine oral tablets inhibit replication influenza virus biocryst pharmaceuticals inc developing injectable formulations peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trials macugen macugen competes primarily visudyne verteporfin injection sold novartis used connection photodynamic therapy lucentis ranibizumab sold genentech inc number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding certain relationships including ongoing financial accounting impact business found item note consolidated financial statements pages included annual report table contents commercial collaborations although currently number collaborations corporate partners govern manufacture sale distribution andor marketing products various territories worldwide following commercial collaborations significant us financial statement perspective significant ongoing collaboration activity exists bristolmyers squibb company bms december entered collaboration bms develop commercialize single tablet regimen truvada bmss sustiva united states combination approved use united states july sold name atripla bms structured collaboration joint venture forming limited liability company called bristolmyers squibb gilead sciences llc terms collaboration bms granted royalty free sublicenses joint venture use respective company owned technologies return granted license joint venture use intellectual property results collaboration economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable truvada emtricitabine tenofovir disoproxil fumarate sustiva efavirenz respectively since net selling price truvada may change time relative net selling price sustiva bmss respective economic interests joint venture may vary annually bms share marketing sales efforts parties providing equivalent sales force efforts levels agreed annually bms us daily operations joint venture governed four primary joint committees formed bms us responsible accounting financial reporting tax reporting product distribution joint venture september bms amended joint ventures collaboration agreement allow joint venture sell atripla canada agreement continue terminated mutual agreement parties addition either party may terminate partys participation collaboration within days launch least one generic version partys single agent products double agent products nonterminated party right continue sell atripla shortterm obligation pay royalties terminated party december entered collaboration bms sets forth terms conditions bms commercialize atripla european union norway iceland switzerland liechtenstein either bms third party distributor act selling party countries responsible among things receiving processing customer orders warehousing product collecting sales handling returns manufacturing atripla coordinated us primarily responsible distribution logistics general parties share revenues outofpocket expenses proportion net selling prices truvada respect us efavirenz respect bms agreement terminate upon expiration last expire patent affords market exclusivity atripla one components european countries covered agreement prior time either party may terminate agreement reason termination effective december nonterminating party right continue sell atripla obligated pay terminating party certain royalties three year period following effective date termination event nonterminating party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier f hoffmannla roche ltd together hoffmannla roche inc roche september entered development license agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche original agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay us percentage net sales roche generated tamiflu sales agreement received upfront payment amount million entitled receive additional milestone payments million upon achievement certain development table contents regulatory objectives received milestone payments october roche also made cash payment us amount million related reimbursement certain research preclinical development expenses obligation prosecute maintain certain patents agreement november entered first amendment supplement original agreement roche amendment eliminated cost goods adjustments royalty calculation retroactive calendar year future calculations amendment also provided formation joint manufacturing committee review roches manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis committees consists representatives roche us amendment option provide specialized sales force supplement roches us marketing efforts tamiflu exercised date agreement roches obligation pay royalties us terminate countrybycountry basis patents providing exclusivity tamiflu countries expire roche may terminate agreement reason case rights tamiflu would revert us either party may terminate agreement response material breach party glaxosmithkline inc gsk march exclusively sublicensed gsk rights ambrisentan active pharmaceutical ingredient letairis marketed name volibris territories outside united states certain hypertensive conditions territories outside united states license agreement received upfront payment million subject achievement specific milestones eligible receive total additional milestone payments million december received million potential milestone payments addition receive royalties based net sales volibris gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses volibris gsk territories term license agreement agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals letairis volibris united states canada european economic area party may conduct additional development activities territories expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development agreement gsks obligation pay royalties us terminate countrybycountry basis earlier date generic equivalents sold country achieve certain percentage total prescriptions product plus generic equivalents fifteenth anniversary commercial launch country gsk may terminate agreement reason upon termination events rights product would revert us either party may terminate agreement response material breach party research collaborations currently number collaborations corporate partners govern research development certain compounds drug candidates following research collaborations significant us financial statement perspective significant ongoing collaboration activity exists abbott laboratories inc abbott june entered exclusive worldwide license agreement abbott develop commercialize darusentan conditions except oncology made initial license payments totaling million terms agreement abbott right first negotiation participate us copromotion product right first negotiation become exclusive development commercialization partner japan addition obligated make future milestone payments million upon achievement certain regulatory approvals well pay royalties based net sales table contents successfully commercialize drug indication obligated use commercially reasonable efforts develop commercialize product certain countries commercialize darusentan certain countries abbott may market product affected markets pay us royalty sales darusentan currently studied phase clinical trials treatment patients resistant hypertension december made million milestone payments obligation pay royalties terminate country bycountry basis patents providing exclusivity product countries expire may terminate agreement certain circumstances including determine product would reasonable likelihood commercial success case rights responsibilities product would revert abbott either party may terminate agreement response material breach party japan tobacco inc japan tobacco march entered licensing agreement japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco would retain rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize product treatment hiv bear costs expenses associated commercialization efforts terms agreement paid upfront license fee million obligated make total potential milestone payments million upon achievement certain clinical regulatory commercial objectives additionally obligated pay royalties based net sales territories market product december made total milestone payments million agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party research development addition entering collaborations companies universities medical research institutions seek add existing portfolio products internal discovery clinical development programs active inlicensing product acquisition strategy acquisitions myogen inc corus pharma inc acquired navitas assets llcs assets related cicletanine business evaluating potential treatment pah research scientists foster city san dimas california durham north carolina seattle washington boulder westminster colorado engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs product development efforts cover wide range medical conditions including hivaids liver disease cardiovascular disease respiratory disease summary key products corresponding current stages development additional information development pipeline visit website wwwgileadcom table contents product candidate description marketing applications pending aztreonam inhalation solution treatment new drug application nda aztreonam inhalation solution treatment cystic fibrosis cystic fibrosis cf submitted us food drug administration fda november september received complete response letter fda informing us fda approve nda aztreonam inhalation solution treatment cf current form requesting conduct additional phase clinical study november filed request formal dispute resolution fda february response appeal fda notified us reiterating position need conduct another clinical study aztreonam inhalation solution resubmit nda also submitted marketing authorization application european union received notice acceptance priority review health canada approval canada still awaiting responses respective regulatory bodies phase ambrisentan ambrisentan oral era evaluated treatment idiopathic pulmonary fibrosis ipf darusentan darusentan oral era investigated addon therapy patients resistant hypertension elvitegravir elvitegravir oral integrase inhibitor evaluated part combination therapy hiv treatment experienced patients preparing phase ambrisentan ambrisentan also going evaluated treatment chronic allograft injury kidney transplant recipients pulmonary hypertension patients ipf phase gs gs oral nonnucleoside polymerase inhibitor evaluated part combination therapy peginterferon alfa ribavirin treatmentnave hepatitis c virus hcv infected patients genotype gs gs inhaled coformulation fosfomycin tobramycin evaluation bacterial infections associated cf gs gs oral caspase inhibitor evaluation treatment inflammatory fibrotic conditions including hcv nonalcoholic steatohepatitis aztreonam inhalation solution aztreonam inhalation solution also evaluated bronchiectasis cicletanine cicletanine oral agent development pah preparing phase gs gs pharmacoenhancer development boosting agent certain hiv medicines elvitegravir gs truvada fourinone fixed dose regimen combines elvitegravir gs tenofovir disoproxil fumarate emtricitabine evaluation treatment hivaids treatmentnave patients table contents product candidate description phase gs gs nucleotide analogue evaluation topical ointment patients external genital perianal warts caused human papilloma virus infection gs gs nucleotide analogue evaluation patients nonhodgkins lymphoma chronic lymphocytic leukemia gs gs oral epithelial sodium channel blocker designed increase airway hydration patients pulmonary disease total research development expenses million compared million million patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows actual estimated expiration dates united states europe primary patents patents may issue pending applications cover compounds marketed products us patent european patent products expiration expiration vistide hepsera letairis ambisome tamiflu macugen viread emtriva truvada atripla supplementary protection certificate protection obtained certain european countries confers auxiliary form patent exclusivity based european patent expiration date viread one components truvada patents covering active pharmaceutical ingredients truvada atripla viread emtriva hepsera letairis vistide held third parties acquired exclusive rights patents agreements table contents parties patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera applications pending various countries asia including china relate specific forms formulations hepsera asia major market therapies hepatitis b infection indication hepsera developed patent covering flolan market exclusivity protection expired result one generic pharmaceutical companies may launch generic version flolan united states may obtain patents certain products many years obtain marketing approval products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions example extensions patents many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third parties allow us use technology certain required could obtain license third party technology could obtain one reasonable cost able obtain required license alternative technologies may unable develop commercialize products business could adversely affected example aware body patents may relate operation leap restricted distribution program designed support letairis addition actelion markets tracleer applied patent claims method use eras treatment ipf issued patent may interfere efforts commercialize era ambrisentan ipf patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful results operations may adversely affected events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation examination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection example public patent foundation filed requests reexamination united states patent trademark office pto challenging four patents related tenofovir disoproxil fumarate active ingredient truvada atripla viread pto granted requests issued nonfinal rejections four patents step common proceeding initiate reexamination process pto confirmed patentability four patents although successful responding pto office actions instance similar organizations may still challenge patents foreign jurisdictions example april brazilian health ministry citing pending us patent reexamination proceedings grounds rejection requested table contents brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issued final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate filed brazil filed appeal patent authority responding questions raised rejection predict outcome proceeding tenofovir disoproxil fumarate patent application unable successfully appeal decision patent authority courts brazilian patent authority reject tenofovir disoproxil fumarate patent application tenofovir disoproxil fumarate patent application rejected brazilian patent authority brazilian government would likely purchase generic tenofovir disoproxil fumarate would significantly reduce sales hiv products brazil pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries africa asia including china permit enforcement patents third party manufacturers able sell generic versions products countries part approval process products fda granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully example november received notice teva pharmaceuticals submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit us district court new york teva infringement two emtricitabine patents predict ultimate outcome action may spend significant resources defending patents unsuccessful lawsuit original claims patents may narrowed invalidated patent protection truvada united states would shortened expire instead also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions table contents august pto adopted new rules scheduled become effective november october gsk successfully obtained preliminary injunction implementation rules april court ruled support gsks challenge rules obtained permanent injunction implementation rules would restricted number claims permitted patent application number continuing patent applications filed following courts ruling pto filed notice appeal federal court appeals pto successfully appeals courts decision rules implemented may limited ability obtain broad patent coverage products product candidates may allow competitors market products similar obtain patent coverage closely related products manufacturing raw materials manufacturing strategy contract third parties manufacture majority solid dose products also rely corporate partners manufacture certain products additionally manufacturing facilities san dimas california edmonton alberta canada dublin cork ireland manufacture certain products clinical commercial uses contract third parties manufacture certain products clinical commercial purposes including truvada atripla viread emtriva hepsera vistide use multiple third party contract manufacturers manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients truvada atripla emtricitabine active pharmaceutical ingredient emtriva one active pharmaceutical ingredients truvada atripla adefovir dipivoxil active pharmaceutical ingredient hepsera also rely third party contract manufacturers tablet capsulate products example use multiple third party contract manufacturers tablet truvada atripla viread emtriva hepsera emtriva capsulation also completed third party contract manufacturers rely single third party supplier tablet letairis also manufacturing agreements corporate partners roche third parties responsible manufacturing tamiflu agreement roche joint manufacturing committee composed representatives roche us opportunity review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu gsk affiliates third parties manufacture flolan distribution us united states terms distribution supply agreement gsk san dimas facility manufacture fill package products manufacture ambisome exclusively facility depend single supplier high quality cholesterol used manufacture ambisome fill finish macugen exclusively facilities san dimas manufacturing agreements osi pfizer osi currently provides pegaptanib sodium active pharmaceutical ingredient macugen also fill package drug product truvada atripla viread emtriva hepsera finished forms facilities san dimas fda recently approved facilities san dimas manufacture aztreonam inhalation solution subject fda approval product delivery device edmonton alberta facility carry process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational products conduct chemical development activities improve existing commercial manufacturing processes addition utilize site manufacture emtricitabine also manufacture active pharmaceutical ingredient letairis exclusively edmonton site although another supplier qualified make active pharmaceutical ingredient letairis fill package drug product truvada atripla viread emtriva hepsera finished forms facilities near dublin ireland also perform quality control testing final labeling packaging table contents ambisome distribution many products european union elsewhere facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral products well product packaging activities manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations third party manufacturers corporate partners subject fdas current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards similar regulations effect countries manufacturing operations also subject routine inspections regulatory agencies additionally third party manufacturers corporate partners independent entities subject unique operational financial risks control third party manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected believe technology use manufacture products proprietary products manufactured third party contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements third party manufacturers intended restrict manufacturers using revealing technology certain third party manufacturers comply restrictions addition third party manufacturers could develop technology related work perform us may need manufacture products could required enter additional agreements third party manufacturers want use technology allow another manufacturer use technology third party manufacturer could refuse allow us use technology could demand terms use technology acceptable us need access certain supplies products manufacture products delivery material suppliers interrupted reason unable purchase sufficient quantities raw materials used manufacture products may unable ship certain products commercial supply supply product candidates development clinical trials addition products materials utilize operations made one facility example manufacture ambisome fill finish macugen exclusively facilities san dimas california event natural disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome macugen meet market needs product candidate aztreonam inhalation solution pending fda approval dependent four different singlesource suppliers first aztreonam active pharmaceutical ingredient aztreonam inhalation solution manufactured single supplier single site second administered lungs patients device made single supplier single site third fda recently approved facilities san dimas manufacture aztreonam inhalation solution subject fda approval product delivery device san dimas facility manufacturing site authorized manufacture aztreonam inhalation solution although pursuing fda approval third party manufacturer fourth diluent aztreonam inhalation solution manufactured single manufacturer single site problems single suppliers depend may negatively impact development commercialization efforts future products continue consider developing additional manufacturing capabilities establishing additional third party suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future products ability conduct large scale clinical trials meet customer demand commercial products adversely affected table contents seasonal operations backlog worldwide product sales reflect significant degree seasonality however royalty revenues represented total revenues tamiflu royalties comprised significant portion affected seasonality royalty revenue recognize roches sales tamiflu impacted severity associated flu seasons product delivery response avian influenza pandemic threat part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind application study drug candidate human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials table contents fda approval process believe data phase clinical trials show adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seeking approval sell drug candidate particular use fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including san dimas facilities also must licensed state california compliance local regulatory requirements manufacturing facilities located canada including edmonton alberta facility facilities located near dublin cork ireland also must obtain local licenses permits compliance local regulatory requirements drugs treat serious life threatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible accelerated priority review drugs treatment hiv designated use us presidents emergency plan aids relief may also qualify expedited priority review viread truvada atripla received accelerated approval priority reviews drugs receiving accelerated approval must monitored post marketing clinical trials order confirm safety benefits drug also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penalties drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union table contents includes major countries europe centralized approval procedure used approval one country european union used obtain approval another country european union one two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures separate pricing reimbursement approvals also required countries pricing reimbursement successful commercialization products depends part availability governmental third party payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities third party payors increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices example significant portion sales majority products subject significant discounts list price rebate obligations addition increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product revenues profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions significant changes federal medicare system recent years united states could impact pricing products medicare prescription drug improvement modernization act medicare beneficiaries able elect coverage prescription drugs medicare part prescription drug program began january although benefited patients transitioning medicaid medicare part since longer term impact medicare part business yet clear us impact depend part specific decisions regarding level coverage provided therapeutic categories products included terms coverage provided extent preference given selected products category third party payors providing medicare part coverage attempted negotiate price concessions pharmaceutical manufacturers addition discussions taking place federal level pass legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare pricing increasing pressure lower prescription drug prices may limit drug access medicare part enrollees medicare patients pay coinsurance may influence products recommended physicians selected patients results operations could materially adversely affected reimbursement changes emerging medicare prescription drug coverage legislation addition federal medicare proposals state medicaid drug payment changes could also lower payment products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules additionally additional statutory regulatory changes including potential changes medicare part health care reform federal state levels could adversely affect payment drugs demand product time states already enacted health care reform legislation federal government individual state governments continue consider health care reform policies legislation pricing reimbursement environment products may change future become challenging due among reasons new policies new presidential administration new health care legislation passed congress ryan white program largest federal program designed provide care support services people living hiv united states provides funding hiv products state aids drug table contents assistance programs adap many patients uninsured underinsured federal funding appropriated congress year provided cities states providers organizations addition federal funding states localities provide additional funding ryan white services program due reauthorized september unless otherwise extended congress may changes program would change decrease funding available hiv products example appropriations ryan white held amount previous years people access drugs adap likely face pressures provide even greater discounts drugs purchased program addition falling state revenues budget cuts may result reduction state local funding ryan white could lead increased demand patient assistance programs offer hiv products free charge eligible patients europe success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months example launched atripla france remain reimbursement discussions french government authorities reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates retrospective taxes profit control expect prices prescription pharmaceuticals decline life product volumes increase recent years many countries european union increased amount required discounts products expect continue countries attempt manage health care expenditures especially light global economic downturn new drugs come market may face significant price decreases products across european countries believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth government agencies also issue regulations guidelines directly applicable us products addition time time professional societies practice management groups private healthscience foundations organizations publish guidelines recommendations directed certain health care patient communities recommendations guidelines may relate matters product usage dosage route administration use related competing therapies consequently result increased decreased usage products health care fraud abuse laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws prohibit anyone knowingly willingly presenting causing presented payment third party payors including medicare medicaid claims reimbursed drugs services false fraudulent claims items services provided claimed claims medically unnecessary items services sales marketing activities may subject scrutiny laws violations fraud abuse laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid government allege convict us violating laws could material adverse effect results operations table contents november received subpoena united states attorneys office san francisco requesting documents regarding marketing medical education programs truvada viread emtriva complying us attorneys subpoena continue cooperate related governmental inquiry compulsory licenses number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread result discussions brazilian government reached agreement brazilian health ministry may reduce price viread brazil approximately addition concerns cost availability tamiflu related potential avian flu pandemic generated international discussions compulsory licensing tamiflu patents example canadian government may allow canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canadas access medicines regime furthermore roche issued voluntary licenses permit third party manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit third party manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement patents manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales employees january approximately fulltime employees believe good relations employees environment seek comply applicable statutory administrative requirements concerning environmental quality made continue make expenditures environmental compliance protection expenditures compliance environmental laws expected material effect capital expenditures results operations competitive position information subject information requirements exchange act therefore file periodic reports proxy statements information sec reports proxy statements information may obtained visiting public reference room sec f street ne washington dc calling sec sec sending electronic message sec publicinfosecgov sending fax sec addition sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically table contents mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act filings available free charge upon request item risk factors evaluating business carefully consider following risks addition information annual report manifestation following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face substantial portion revenues derived sales hiv products unable maintain continue increasing sales hiv products results operations may adversely affected currently dependent sales products treatment hiv especially truvada atripla support existing operations hiv products contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutics treatment paradigm hiv change causing nucleosidebased therapeutics fall favor unable continue increasing hiv product sales results operations would likely suffer would likely need scale back operations including spending research development rd efforts hiv product sales year ended december billion total revenues sales truvada atripla accounted respectively total hiv product sales may able sustain growth rate sales hiv products reasons stated risk factor section particular following reasons hiv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues hiv products mature private insurers government reimbursers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products consists patients already taking hiv drugs successful encouraging physicians change patients regimens include hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing market share may affected table contents inability accurately estimate demand products well sales fluctuations result inventory levels held wholesalers pharmacies non retail customers make difficult us accurately forecast sales may cause earnings fluctuate could adversely affect financial results stock price year ended december approximately product sales united states three wholesalers cardinal health inc mckesson corp amerisourcebergen corp us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesale locations inventory management agreements control buying patterns adverse changes economic conditions factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers orders us even though end user demand changed example fourth quarter strong prescription demand truvada atripla fully reflected revenues fourth quarter believe quarter inventories drawn within retail distribution channel inventory distribution channel fluctuates quarter quarter may continue see mismatch prescription demand products revenues addition nonretail sector united states includes government institutions including state aids drug assistance programs adap correctional facilities large health maintenance organizations tends even less consistent terms buying patterns often causes quarter quarter fluctuations necessarily mirror purchasing patterns seen within retail sector example first quarter observed large nonretail purchases small number state adaps purchase centrally significant warehousing capacity believe purchases driven grant cycle federal adap funds rather current patient demand tempered orders associated product sales revenues earnings second quarter organizations depleted increased inventory levels established first quarter expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future estimate future demand products consider shelf life inventory regularly review realizability inventory actual demand less estimated demand could required record inventory writedowns would adverse impact results operations stock price fail commercialize new products expand indications existing products prospects future revenues may adversely affected introduce new products market increase sales existing products able increase maintain total revenues continue expand rd efforts example december committee medicinal product human use european medicines agency emea granted marketing authorization atripla european union treatment hiv infection adults virologic suppression hiv rna levels less copiesml current combination antiretroviral therapy three months patients must experienced virological failure prior antiretroviral therapy must known harbored virus strains mutations conferring significant resistance three components contained atripla restriction atriplas use european union prevent us promoting atripla use patients currently achieving reduction viral load use antiretroviral therapy including newly diagnosed patients seek expand indication atripla european union emea may require us perform additional clinical trials may unable complete unable expand indication atripla include broader population patients impact future sales atripla table contents european union unknown could limited markets including united states restrictions addition sales atripla may increase expense product sales component products overall total revenues gross margin may increase atripla sales increase marketing authorization application submitted us aztreonam inhalation solution treatment cystic fibrosis cf united states delayed received complete response letter fda informing us fda approve application current form requesting conduct additional phase clinical study november filed request dispute resolution fda determine whether analyses existing data could lead approval whether need conduct additional study february response appeal fda notified us reiterating position need conduct another clinical study aztreonam inhalation solution resubmit new drug application nda existing data ongoing additional clinical trial may commence satisfy fda concerns may support fda approval aztreonam inhalation solution may cause us considerable expense may lead delays cause us abandon development product also risks health authorities countries marketing authorization applications pending undertake similar additional reviews would compound risks described significant portion product sales occur outside united states currency fluctuations may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates us dollar strengthens foreign currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business net foreign currency exchange impact revenues pretax earnings includes revenues expenses generated outside united states favorable million million respectively compared recently us dollar appreciated major european currencies amount favorable impact product sales resulted previously relatively weak us dollar decreased use foreign currency forward option contracts hedge percentage forecasted international sales primarily denominated euro also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid predict future fluctuations foreign currency exchange rate us dollar us dollar continues appreciate certain currencies hedging program sufficiently offset effects appreciation results operation adversely affected stock price may decline face significant competition face significant competition large pharmaceutical biotechnology companies substantially greater resources addition competitors products operated fields compete longer hiv products compete primarily products glaxosmithkline inc gsk markets fixed dose combination products compete truvada atripla hepsera viread treatment chronic hepatitis b compete primarily products produced gsk bristolmyers squibb company bms novartis pharmaceuticals corporation novartis united states european union china ambisome compete primarily products produced merck co inc merck pfizer inc pfizer addition aware least two lipid formulations claim similarity ambisome becoming available outside united states including possible entry one formulation greece formulations may reduce market demand table contents ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association letairis competes directly actelion pharmaceuticals us inc actelion indirectly pah products united therapeutics corporation pfizer tamiflu competes products sold gsk generic competitors aztreonam inhalation solution treatment cf approved marketing compete product marketed novartis addition number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs significant safety issues arise marketed products product candidates future sales may reduced would adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases postapproval use products used longer periods time many patients underlying health problems taking numerous medicines expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products product letairis approved fda june member class compounds called endothelin receptor antagonists pose specific risks including serious risks liver injury birth defects risks letairis available letairis education access program leap restricted distribution program intended help physicians patients learn risks associated product assure appropriate use product product used additional patients may discover new risks associated letairis may result changes distribution program additional restrictions use letairis may decrease demand product example since launch letairis cases edema certain patients taking letairis reported information recently added product label may negatively impact demand product serious safety resistance drug interaction issues arise marketed products including letairis sales products could limited halted us regulatory authorities results operations would adversely affected operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda comparable regulatory agencies countries continuing clinical trials truvada atripla viread hepsera emtriva ambisome letairis currently approved additional uses anticipate file marketing approval additional countries additional indications products next several years products may fail receive marketing approvals timely basis september received complete response letter fda informing us fda approve nda aztreonam inhalation solution treatment cf current form requesting conduct additional phase clinical study november filed request dispute resolution table contents fda determine whether analyses existing data could lead approval whether need conduct additional study february response appeal fda notified us reiterating position need conduct another clinical study aztreonam inhalation solution resubmit nda existing data ongoing clinical trials additional clinical trial may commence satisfy fda concerns may support fda approval aztreonam inhalation solution may cause us considerable expense may lead delays cause us abandon development product also risks health authorities countries marketing authorization applications pending undertake similar additional reviews would compound risks described addition marketed products manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution september president bush signed law food drug administration amendments act significantly expanded fdas authority including among things require sponsors marketed products conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk mandate labeling changes products point products lifecycle based new safety information require sponsors implement risk evaluation mitigation strategy product could include medication guide patient package insert communication plan healthcare providers elements fda deems necessary assure safe use drug could include imposing certain restrictions distribution use product failure comply requirements imposed sponsor fda could result significant civil monetary penalties results anticipated timelines clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted may also face challenges clinical trial protocol design clinical trials product candidates pipeline delayed terminated prospects future revenue growth would adversely impacted example face numerous risks uncertainties product candidates including elvitegravir novel hiv integrase inhibitor darusentan treatment resistant hypertension ambrisentan treatment idiopathic pulmonary fibrosis ipf currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others table contents pipeline completed timely basis prospects future revenue growth may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn decrease revenues harm business due reliance third party contract research organizations conduct clinical trials unable directly control timing conduct expense quality clinical trials extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent third party contract research organizations cros control perform clinical studies including document preparation site identification screening preparation prestudy visits training program management bioanalytical analysis dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed third party cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely impacted depend relationships companies sales marketing performance revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance certain territories include collaborations bms atripla united states europe canada roche tamiflu gsk ambrisentan territories outside united states countries rely international distributors sales truvada viread hepsera emtriva ambisome relationships also involve clinical development products partners reliance collaborative relationships poses number risks including inability control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us particularly light current economic conditions given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan south korea success hepsera table contents territories depends almost entirely efforts gsk regard gsk promotes epivirhbvzeffix product competes hepsera consequently gsks marketing strategy hepsera may influenced promotion epivirhbvzeffix receive royalties gsk equal percentage gsks net sales hepsera well net sales gsks epivirhbvzeffix gsk fails devote sufficient resources succeed developing commercializing hepsera territories potential revenues sales hepsera territories may substantially reduced addition letairis distributed third party specialty pharmacies pharmacies specializing dispensing medications complex chronic conditions may require high level patient education ongoing counseling use specialty pharmacies requires significant coordination sales marketing medical affairs regulatory affairs legal finance organizations involves risks including limited risks specialty pharmacies provide us accurate timely information regarding inventories patient data safety complaints effectively sell support letairis devote resources necessary sell letairis volumes within time frames expect able satisfy financial obligations us others cease operations also rely third party administer leap restricted distribution program designed support letairis third party provides information education prescribers patients risks letairis confirms insurance coverage investigates alternative sources reimbursement assistance ensures fulfillment risk management requirements mandated letairis fda coordinates controls dispensing patients third party specialty pharmacies failure third party specialty pharmacies distribute letairis perform expected may result regulatory action fda decreased letairis sales either would harm business dependent supplier inhalation device delivers aztreonam inhalation solution regulatory approval obtained distribute device specialty pharmacies distribution channels control many key aspects related device example supplier could encounter issues regulatory agencies related device unable supply sufficient quantities device time commercial launch following launch moreover device subject separate reimbursement approval process event supplier unable obtain reimbursement approval receives approval lowerthanexpected price sales aztreonam inhalation solution may adversely affected addition may able obtain adequate supplies inhalation devices previously described issues may limit delay commercial launch aztreonam inhalation solution would adversely affect financial results existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental third party payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities third party payors increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices example significant portion sales majority products subject significant discounts list price rebate obligations addition table contents increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product revenues profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general europe success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months example launched atripla france remain reimbursement discussions french government authorities reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates retrospective taxes profit control expect prices prescription pharmaceuticals decline life product volumes increase recent years many countries european union increased amount discounts required products expect continue countries attempt manage health care expenditures especially light global economic downturn new drugs come market may face significant price decreases products across european countries believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth results operations could adversely affected current future health care reforms legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions significant changes federal medicare system recent years united states could impact pricing products medicare prescription drug improvement modernization act medicare beneficiaries able elect coverage prescription drugs medicare part prescription drug program began january although benefited patients transitioning medicaid medicare part since longer term impact medicare part business yet clear us impact depend part specific decisions regarding level coverage provided therapeutic categories products included terms coverage provided extent preference given selected products category third party payors providing medicare part coverage attempted negotiate price concessions pharmaceutical manufacturers addition discussions taking place federal level pass legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare pricing increasing pressure lower prescription drug prices may limit drug access medicare part enrollees medicare patients pay coinsurance may influence products recommended physicians selected patients results operations could materially adversely affected reimbursement changes emerging medicare prescription drug coverage legislation addition federal medicare proposals state medicaid drug payment changes could also lower payment products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules additionally additional statutory regulatory changes including potential changes medicare part health care reform federal state levels could adversely affect payment drugs demand product time states already enacted health care reform legislation federal government individual state governments continue consider health care reform policies legislation pricing reimbursement environment products may change future become challenging due among reasons new policies new presidential administration new health care legislation passed congress table contents ryan white program largest federal program designed provide care support services people living hiv united states provides funding hiv products state aids drug assistance programs adap many patients uninsured underinsured federal funding appropriated congress year provided cities states providers organizations addition federal funding states localities provide additional funding ryan white services program due reauthorized september unless otherwise extended congress may changes program would change decrease funding available hiv products example appropriations ryan white held amount previous years people access drugs adap likely face pressures provide even greater discounts drugs purchased program addition falling state revenues budget cuts may result reduction state local funding ryan white could lead increased demand patient assistance programs offer hiv products free charge eligible patients expenses associated clinical trials may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval expensive difficult accurately predict control amount timing expenses quarter quarter uneven unexpected spending programs may cause operating results fluctuate quarter quarter stock price may decline success depend significant degree ability protect patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology patents proprietary rights important business success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential period time patent issued result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents addition competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful results operations may adversely affected events table contents time time certain individuals entities may challenge patents example public patent foundation filed requests reexamination united states patent trademark office pto challenging four patents related tenofovir disoproxil fumarate active ingredient truvada atripla viread pto granted requests issued nonfinal rejections four patents step common proceeding initiate reexamination process pto confirmed patentability four patents although successful responding pto office actions instance similar organizations may still challenge patents foreign jurisdictions example april brazilian health ministry citing pending us patent reexamination proceedings grounds rejection requested brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issued final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate filed brazil filed appeal within patent authority responding questions raised rejection predict outcome proceeding tenofovir disoproxil fumarate patent application unable successfully appeal decision patent authority courts brazilian patent authority reject tenofovir df patent application tenofovir disoproxil fumarate patent application rejected brazilian patent authority brazilian government would likely purchase generic tenofovir disoproxil fumarate would significantly reduce sales hiv products brazil patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hepatitis b infection indication hepsera developed flolans patent market exclusivity protection expired result one generic pharmaceutical companies may launch generic version flolan united states may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions part approval process products fda granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully example november received notice teva pharmaceuticals submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit us district court new york teva infringement two emtricitabine patents predict ultimate outcome action may spend significant resources defending patents unsuccessful lawsuit original claims patents may narrowed invalidated patent protection truvada united states would shortened expire instead august pto adopted new rules scheduled become effective november october gsk successfully obtained preliminary injunction implementation rules april court ruled support gsks challenge rules obtained permanent table contents injunction implementation rules would restricted number claims permitted patent application number continuing patent applications filed following courts ruling pto filed notice appeal federal court appeals pto successfully appeals courts decision rules implemented may limited ability obtain broad patent coverage products product candidates may allow competitors market products similar obtain patent coverage closely related products success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware body patents may relate operation leap restricted distribution program designed support letairis addition actelion markets tracleer applied patent claims method use endothelin receptor antagonists eras treatment ipf issued patent may interfere efforts commercialize era ambrisentan ipf furthermore use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations depend third parties perform manufacturing activities effectively timely basis majority solid dose products addition roche either third parties responsible manufacturing tamiflu manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations third party manufacturers corporate partners subject fdas current good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards similar regulations effect countries manufacturing operations also subject routine inspections regulatory agencies additionally third party manufacturers corporate partners independent entities subject unique operational financial risks control third party manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected ability successfully manufacture commercialize aztreonam inhalation solution approved depend upon ability manufacture multi product facility aztreonam monobactam gramnegative antibiotic currently plan manufacture third parties multiproduct manufacturing facilities historically fda permitted manufacture monobactams multiproduct manufacturing facilities however assurance fda continue allow practice currently singleproduct facility dedicated manufacture aztreonam inhalation solution engaged contract manufacturer singleproduct facility aztreonam inhalation solution fda prohibits manufacture monobactam antibiotics like aztreonam inhalation solution multiproduct manufacturing facilities future may able procure singleproduct manufacturing facility timely manner would adversely affect commercial supplies aztreonam inhalation solution anticipated financial results attributable product approved table contents may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues need access certain supplies products conduct clinical trials manufacture products light economic downturn increased difficulty purchasing certain raw materials used manufacturing process unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues suppliers key components materials must named nda filed fda product candidate seeking fda approval significant delays occur qualification new supplier required even manufacturer qualified fda manufacturer must continue expend time money effort area production quality control ensure full compliance gmp manufacturers subject regular periodic inspections fda following initial approval result inspections fda determines equipment facilities laboratories processes comply applicable fda regulations conditions product approval fda may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand would turn decrease revenues harm business addition delivery material suppliers interrupted reason may unable ship certain products commercial supply supply products development clinical trials addition products materials utilize operations made one facility example manufacture ambisome fill finish macugen exclusively facilities san dimas california event natural disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome macugen meet market needs product candidate aztreonam inhalation solution pending fda approval dependent four different singlesource suppliers first aztreonam active pharmaceutical ingredient aztreonam inhalation solution manufactured single supplier single site second administered lungs patients device made single supplier single site third fda recently approved facilities san dimas manufacture aztreonam inhalation solution subject fda approval product delivery device san dimas facility manufacturing site authorized manufacture aztreonam inhalation solution although pursuing fda approval third party supplier fourth diluent aztreonam inhalation solution manufactured single manufacturer single site addition depend single supplier high quality cholesterol used manufacture ambisome also depend single suppliers active pharmaceutical ingredient tableting letairis problems single suppliers depend may negatively impact development commercialization efforts face credit risks european customers may adversely affect results operations european product sales governmentowned supported customers greece italy portugal spain subject significant payment delays due government funding reimbursement practices resulted may continue result increase days sales outstanding due average length time accounts receivable outstanding accounts receivable countries totaled approximately million december million days past due historically receivables accumulated period time settled large lump sum payments government funding became available significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected table contents product revenues gross margin could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly truvada viread agreed make available substantially reduced prices countries participating gilead access program atripla merck distributes substantially reduced prices hiv infected patients developing countries august agreement revenues would adversely affected addition established partnerships ten indian generic manufacturers distribute highquality lowcost generic versions tenofovir disoproxil fumarate developing world countries including india generic versions medications licenses reexported united states europe markets outside countries revenues would adversely affected addition purchases products countries selling prices relatively low resale countries selling prices relatively high may adversely impact revenues gross margin may cause sales fluctuate quarter quarter example european union required permit products purchased one country sold another country purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter difficult forecast addition wholesalers may attempt arbitrage pricing differential countries purchasing excessive quantities products activities may result fluctuating quarterly sales certain countries reflect actual demand products customers quarterly fluctuations may impact earnings could adversely affect stock price example experienced increased sales hiv products france believe portion products reexported countries resold higher prices sales truvada viread france countries sales reexported may continue fluctuate although established order management system france december manage truvada viread sales facilitate adequate appropriate supply products commensurate market demand france assurance management system effective exporting activities continue france european countries elsewhere result results operations could adversely affected countries may required grant compulsory licenses products face generic competition products number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread result discussions brazilian government reached agreement brazilian health ministry may reduce price viread brazil approximately addition concerns cost availability tamiflu related potential avian flu pandemic generated international discussions compulsory licensing tamiflu patents example canadian government may allow canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canadas access medicines regime furthermore roche issued voluntary licenses permit third party table contents manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit third party manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement patents third party manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others recent years coverage availability product liability insurance decreased addition cost defend lawsuits pay damages product liability claims may exceed coverage unable maintain adequate coverage claims exceed coverage financial condition ability clinically test product candidates market products adversely impacted addition negative publicity associated claims regardless merit may decrease future demand products impair financial condition assumptions used determine selfinsurance levels could wrong materially impact business continually evaluate levels selfinsurance based historical claims experience demographic factors severity factors actuarial assumptions however future occurrences claims differ assumptions historical trends business financial results financial condition could materially impacted claims expenses expensive litigation government investigations may reduce earnings november received notice teva pharmaceuticals submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit us district court new york teva infringement two emtricitabine patents predict ultimate outcome action may spend significant resources defending patents unsuccessful lawsuit original claims patents may narrowed invalidated patent protection truvada united states would shortened expire instead addition along certain officers former officer named defendants class action lawsuit alleging violations federal securities laws lawsuit dismissed united states district court northern district california august united states court appeals ninth circuit reversed dismissal remanded case district court february filed petition writ certiorari supreme court united states requesting court review judgment court appeals supreme court reviews petition case continues district court november received subpoena us attorneys office san francisco requesting documents regarding marketing medical education programs truvada viread table contents emtriva cooperating continue cooperate related governmental inquiry outcome class action lawsuit lawsuits brought us investigation investigations brought us inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us could significantly reduce earnings cash flows harm business changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings finalization federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact net income income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions resolution one exposures reporting period could material impact results operations period changes accounting may affect financial position results operations us generally accepted accounting principles related implementation guidelines interpretations highly complex involve subjective judgments changes rules interpretation adoption new pronouncements application existing pronouncements changes business could significantly affect financial position results operations example may financial accounting standards board fasb issued fasb staff position apb accounting convertible debt instruments may settled cash upon conversion including partial cash settlement fsp apb fsp apb addresses instruments commonly referred instrument c emerging issues task force issue convertible bonds issuer option settle cash upon conversion requires issuer settle principal amount cash conversion spread cash net shares issuers option fsp apb requires issuers instruments account liability equity components separately bifurcating conversion option debt instrument classifying conversion option equity accreting resulting discount debt additional interest expense expected life debt fsp apb effective fiscal years beginning december interim periods within fiscal years requires retrospective application periods presented early application permitted expect adoption fsp apb material impact consolidated financial position results operations based requirements fsp apb estimate fsp apb effective current comparative periods would reported additional interest expense related convertible senior notes approximately million million million respectively addition december fasb issued statement financial accounting standards sfas revised business combinations sfas r sfas r establishes principles requirements recognizing measuring assets acquired liabilities assumed noncontrolling interests acquiree business combination sfas r also provides guidance recognizing measuring goodwill acquired business combination requires purchased inprocess research development table contents capitalized fair value intangible assets time acquisition requires acquisitionrelated expenses restructuring costs recognized separately business combination expands definition constitutes business requires acquirer disclose information users may need evaluate understand financial effect business combination sfas r effective prospective basis impact business combination transactions acquisition date occurs fiscal years beginning december depending nature magnitude future business combination transactions sfas r may material impact consolidated financial position andor results operations fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms unsuccessful recruitment retention efforts business may harmed item b unresolved staff comments applicable item properties corporate headquarters including principal offices commercial administrative research development rd facilities located foster city california january purchased approximately acres land office building located velocity way foster city purchase buildings foster city lease facilities foster city san dimas california house manufacturing warehousing rd activities addition also lease facilities durham north carolina boulder westminster colorado seattle washington house administrative rd activities international headquarters include commercial medical administrative facilities located leased london area united kingdom also lease facilities dublin area ireland house manufacturing distribution activities acquired manufacturing facility cork ireland september connection acquisition nycomed limited transferred certain operations dublin area site facility utilize site primarily solid dose tablet manufacturing antiviral products well product packaging activities also manufacturing facility edmonton alberta canada primarily use conduct process research scaleup clinical development candidates manufacturing active pharmaceutical ingredients investigational commercial products chemical development activities improve existing commercial manufacturing processes leased additional facilities house commercial medical administrative activities australia austria belgium canada france germany greece italy netherlands portugal spain sweden switzerland turkey united kingdom table contents believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings november received notice teva pharmaceuticals submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine us patent numbers owned emory university licensed exclusively us invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit us district court new york teva infringement two emtricitabine patents predict ultimate outcome action may spend significant resources defending patents unsuccessful lawsuit original claims patents may narrowed invalidated patent protection truvada united states would shortened expire instead information pertaining certain legal proceedings found heading legal proceedings item note commitments contingencies consolidated financial statements annual report incorporated reference herein item submission matters vote security holders matters submitted vote security holders quarter ended december table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq global select market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception currently expect retain earnings primarily use operation expansion business therefore anticipate paying cash dividends near future effort return value stockholders minimize dilution stock issuances board directors board authorized program repurchase common stock aggregate amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means see note stockholders equity consolidated financial statements pages annual report information regarding repurchase program table contents performance graph following graph compares total stockholder returns past five years two indices standard poors stock index labeled sp index nasdaq biotechnology index labeled nbi index total return index assumes reinvestment dividends paid companies included indices calculated december year composite member sp index nbi index intend use indices comparators stock performance purposes following graph going forward composite member sp index required applicable regulations use index comparator believe nbi index relevant comparator since composed peer companies linesofbusiness similar stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december table contents issuer purchases equity securities october board authorized program repurchase common stock aggregate amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated share repurchase transactions similar arrangements stock repurchase program expires december table summarizes stock repurchase activity three months ended december thousands except per share amounts maximum total number fair value shares total number shares purchased may yet shares average price part publicly purchased purchased paid per share announced programs program october october november november december december total october entered accelerated share repurchase transaction financial institution repurchase million common stock accelerated basis accelerated share repurchase part billion share repurchase program authorized board october terms accelerated share repurchase agreement paid million financial institution settle initial purchase transaction received shares common stock price per share april subject extension certain circumstances well maximum minimum share delivery provisions agreement may receive additional shares financial institution depending average daily volume weightedaverage prices common stock specified period less predetermined discount per share making initial payment million obligated deliver cash shares financial institution except certain limited circumstances case method delivery cash shares common stock would discretion difference total number shares purchased total number shares purchased part publicly announced programs due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations table contents item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement operations data total revenues purchased inprocess research development total costs expenses income loss operations gain warrant provision income taxes net income loss net income loss per sharebasic shares used per share calculationbasic net income loss per sharediluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible senior notes retained earnings accumulated deficit total stockholders equity completed acquisition assets navitas assets llc related cicletanine business aggregate purchase price million allocated purchased inprocess research development iprd completed acquisition myogen inc aggregate purchase price billion billion allocated purchased iprd million allocated deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations million allocated goodwill million allocated net tangible assets also acquired net assets corus pharma inc million million allocated purchased iprd million allocated net table contents gilead sciences inc selected consolidated financial datacontinued deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations million allocated net tangible assets million allocated assembled workforce recognized million royalty revenue relating resolution dispute f hoffmannla roche ltd together hoffmannla roche inc also recorded tax provision benefit million related repatriation qualified foreign earnings american jobs creation act ajca recorded gain million related warrant purchase capital stock eyetech pharmaceuticals inc predecessor osi pharmaceuticals inc completed initial public offering adopted statement financial accounting standards revised sharebased payment modified prospective basis beginning january see notes consolidated financial statements pages annual report issued billion principal amount convertible senior notes private placement entered uncollateralized million term loan agreement facilitate cash dividend distribution part repatriation qualified foreign earnings provisions ajca table contents item managements discussion analysis financial condition results operations following managements discussion analysis mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering life threatening diseases worldwide headquartered foster city california operations north america europe australia market truvada emtricitabine tenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil viread treatment chronic hepatitis b virus hbv ambisome amphotericin b liposome injection treatment severe fungal infections letairis ambrisentan treatment pulmonary arterial hypertension pah vistide cidofovir injection treatment cytomegalovirus infection flolan epoprostenol sodium treatment pulmonary hypertension f hoffmannla roche ltd together hoffmannla roche inc roche markets tamiflu oseltamivir phosphate treatment influenza royaltypaying collaborative agreement us osi pharmaceuticals inc markets macugen pegaptanib sodium injection united states europe treatment neovascular agerelated macular degeneration royaltypaying collaborative agreement us glaxosmithkline inc gsk markets volibris ambrisentan outside united states treatment pah royaltypaying collaborative agreement us business highlights made significant progress various areas business grew product sales significantly executed product approvals product launches multiple territories made progress moving product candidates forward continued strengthen worldwide organization infrastructure support expanded international footprint business activities commercial achievements year included continued rollout atripla european union eu driving growth atripla truvada united states canada launching viread hepatitis b eu united states making gains pah market letairis well continuing expansion sales marketing infrastructure including establishment new international marketing subsidiaries year received marketing authorization viread treatment chronic hepatitis b adults member states european union turkey new zealand australia united states canada along marketing approvals received made significant advances compounds product candidates research development rd pipeline including hiv area received positive feedback us food drug administration fda latter part year regarding development plans elvitegravir novel integrase inhibitor hiv licensed japan tobacco inc gs pharmacoenhancer development boosting agent certain hiv medicines single table contents tablet fixed dose regimen elvitegravir gs truvada fda agreed proposal simultaneously develop three product candidates allowing us eventually support three separate new drug application nda filings four phase clinical studies one study elvitegravir two studies single tablet fixed dose regimen mentioned one study gs result proposal combining second two previously planned phase studies elvitegravir first phase elvitegravir study began dosing third quarter hepatitis c completed dosing patients continuation phase b study gs nonnucleoside polymerase inhibitor began enrolling phase study patients infected hepatitis c virus year completed phase study gs caspase inhibitor licensed lg life sciences expect initiate phase b study second quarter evaluate longer term safety efficacy gs enrolling patients nonalcoholic steadohepatitis phase study gs evaluate safety effect liver enzymes anticipate data study end cardiovascular area completed enrollment one two phase studies darusentan treatment resistant hypertension anticipate data study second quarter continued enroll patients second phase study darusentan anticipate completing enrollment end data available early developing cicletanine pah expect initiate phase clinical trial examining daily twice daily dosing early also preparing initiate phase study ambrisentan patients pulmonary hypertension idiopathic pulmonary fibrosis second quarter respiratory area submitted nda aztreonam inhalation solution treatment cystic fibrosis cf fda november september received complete response letter fda informing us fda approve nda aztreonam inhalation treatment cf requesting additional phase clinical study november filed request formal dispute resolution fda february response appeal fda notified us reiterating position need conduct another clinical study aztreonam inhalation solution resubmit nda also submitted marketing authorization application maa eu received notice acceptance priority review health canada approval canada still awaiting responses respective regulatory bodies also respiratory area began enrolling patients noncf bronchietasis phase study evaluating aztreonam inhalation solution indication initiated phase study fourth quarter evaluate safety tolerability gs novel epithelial sodium channel blocker designed increase airway hydration treatment pulmonary disease fourth quarter also initiated phase study evaluating safety efficacy gs inhaled coformulation fosfomycin tobramycin bacterial infections associated cf financial highlights operating results year led total product sales billion antiviral product sales truvada atripla viread hepsera emtriva increased billion billion key drivers total product sales growth compared continued uptake atripla united states product launches europe atripla contributed billion total antiviral product sales growth atripla product sales increased proportion overall product sales caused total product gross margin decrease expected due primarily efavirenz component atripla sales zero gross margin truvada product sales comprised billion total antiviral product sales truvada product sales increased primarily due continued sales volume growth well favorable foreign currency exchange impact foreign currency fluctuations favorable impact approximately million total revenues million pretax income compared table contents royalty revenues recognized collaborations corporate partners million decrease royalty revenues million decrease royalty revenues due primarily decreased tamiflu sales roche related pandemic planning initiatives worldwide operating expenses include rd selling general administrative sga purchased inprocess research development iprd expenses increased million compared reflecting increased research clinical study activity development pipeline expanded commercial activities worldwide well higher headcount infrastructure technologyrelated costs required support continued growth business continued focused cost control operating margins continue operating margin impacted efavirenz component growing atripla revenue stream declining trend tamiflu royalties cash cash equivalents marketable securities increased million year driven primarily operating cash flows billion strong cash position allowed us complete two accelerated share repurchase transactions well make significant common stock repurchases open market billion stock repurchase program authorized board directors board october expires december repurchased total billion stock repurchase program approximately million shares december remaining authorized amount stock repurchases may made board authorized stock repurchase program million light volatility developments financial markets continued review cash equivalents marketable securities carefully well invest prudently safety preservation principal diversification risk well liquidity investments sufficient meet cash flow requirements continued primary importance investment goals approach helped protect us significant risks credit markets allowing us meet operating cash flow requirements execute opportunities share repurchases outlook anticipate high level productivity financial performance experienced continue operating objectives include expansion commercial markets franchise perspective well leveraging new international marketing subsidiaries established last two years reaching significant rd development timelines continuing strengthen pipeline internally developed andor externally inlicensed purchased opportunities strengthening key alliances commercial standpoint number internal external initiatives may help promote continued growth franchises hiv area favorably impacted presentation important data sets upcoming medical conferences continued testing screening initiatives recent changes hiv treatment guidelines area hepatitis b broad platform educational activities concentrated asian american communities highlighting need screen diagnose link patients care help support viread hbv united states since launch viread hbv august hepatitis sales medical affairs teams concentrated efforts solely promotion viread cardiovascular area continue build presence within pah community support growth letairis mindful conditions current macroeconomic environment could affect ability achieve goals factors could affect business include volatility foreign currency exchange rates government pricing pressures united states internationally well changes financial health andor practices significant business partners customers although yet seen significant changes continue monitor credit foreign currency exchange markets table contents developments health care reform legislation well practices suppliers manufacturers corporate partners customers adjust business processes needed mitigate risks business successes experienced helped us maintain build financially sound business model believe allow us continue expand commercial collaborative rd activities maintain infrastructure ensure quality compliance areas business continue grow business achieve greater operational leverage remain focused profitable revenue growth prudent expense management believe enable solid execution operating objectives critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition allowance doubtful accounts prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various market specific assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results however may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition product sales recognize revenues product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured record estimated reductions revenues government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products estimates deducted gross product sales time revenues recognized reductions gross product sales government rebates significantly impact reported net product sales based upon certain estimates require complex significant judgment management government rebates estimate amounts payable us government managed medicaid programs well certain qualifying federal state foreign government programs reimbursement portions retail price prescriptions filled covered programs government rebates invoiced directly us recorded accrued liabilities consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower price record allowances accounts receivable although may pay rebates countries outside united states date payments made foreign governments represented significant portion total government rebates government programs united states estimate sales allowances based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements us government rebates table contents million million million respectively representing total gross product sales respectively deducted gross product sales based current information available us actual government rebates claimed periods varied less estimates recorded periods december accrued us government rebates million million respectively accrued liabilities allowance million million respectively recorded accounts receivable following table summarizes aggregate activity us government rebates allowance accrued liabilities accounts balance deducted balance beginning charged end year expense accruals year year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total allowance doubtful accounts also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required allowance doubtful accounts balance percentage total accounts receivable materially change december december believe allowance doubtful accounts adequate cover anticipated losses current conditions however significant deterioration factors especially respect government funding reimbursement practices european market could materially change expectations may result increase allowance doubtful accounts prepaid royalties capitalize royalties prepaid cost specifically related emtricitabine royalties paid emory university emory hiv indication based present value future royalty obligation would expect pay emory assuming certain expected future levels product sales incorporating emtricitabine present value future royalty obligation derived using weightedaverage cost capital review quarterly expected future sales levels products indicators might require writedown net recoverable value asset change estimated life prepaid royalty potential indicators impairment include launch significant product competitor significant deviations recognized product sales compared forecast product safety issues recalls table contents amortize prepaid royalties based effective royalty rate derive forecasted hiv product sales incorporating emtricitabine product sales forecasts prepared annually determined using best estimates future activity upon considering factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts including introduction competing product us one competitors hiv market emtricitabine prospectively update royalty rate used amortize prepaid royalties may increase future royalty expense december prepaid royalty asset relating emtricitabine royalties paid emory million amortization expense relating prepaid royalty asset million million million years ended december respectively clinical trial accruals record accruals estimated clinical study costs clinical studies performed third party contract research organizations cros costs significant component rd expenses incurred cro costs million million million respectively accrue costs clinical studies performed cros straightline basis service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros validate accruals quarterly vendors perform detailed reviews activities related significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros generally significant portion total clinical trial costs associated start activities trial patient enrollment extensively outsource clinical trial activities usually perform small portion startup activities inhouse result cros typically perform total startup activities trials including document preparation site identification screening preparation prestudy visits training program management startup costs usually occur within months contract executed milestone event driven nature remaining clinical activities related costs patient monitoring administration generally occur ratably throughout life individual contract study contracts negotiated fixed per unit prices vary length three months single dose phase clinical study two years complex phase clinical study average length contracts upper end range order provide longterm safety efficacy data support commercial launches truvada atripla viread hepsera emtriva letairis material cro contracts terminable us upon written notice generally liable actual effort expended cro certain noncancelable expenses incurred point termination amounts paid advance relating uncompleted services refunded us contract terminated contracts may include additional termination payments become due payable terminate contract additional termination payments recorded becomes probable contract terminated december differences actual estimated activity levels particular study material however management receive complete accurate information vendors underestimates activity levels associated study given point time may record additional potentially significant rd expenses future periods tax provision estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance table contents expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made adjustment made determined likely certain deferred tax assets would realized therefore released related valuation allowance resulted credit goodwill approximately million income tax benefit approximately million million respectively future effective income tax rate may affected factors changes tax laws regulations rates changing interpretation existing laws regulations impact accounting stockbased compensation changes international organization changes overall levels income tax june financial accounting standards board fasb issued fasb interpretation accounting uncertainty income taxes fin interpretation statement financial accounting standards sfas accounting income taxes sfas fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return fin also provides guidance derecognition classification interest penalties accounting interim periods disclosure transition fin effective fiscal years beginning december january adopted fin increased liability unrecognized tax benefits million corresponding charge opening balance accumulated deficit permitted fin addition reclassified million unrecognized tax benefits shortterm income taxes payable noncurrent deferred tax assets longterm income taxes payable date adoption total federal state foreign unrecognized tax benefits million recorded primarily longterm income taxes payable consolidated balance sheet including accrued liabilities related interest million total unrecognized tax benefits million recognized would reduced effective tax rate period recognition permitted provisions fin continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements operations december total federal state foreign unrecognized tax benefits million million respectively including interest million million respectively total unrecognized tax benefits december million million respectively recognized would reduce effective tax rate period recognition reached agreement internal revenue service irs several issues related examinations federal income tax returns result reduced unrecognized tax benefits million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs around certain uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective taxing authorities file federal state foreign income tax returns many jurisdictions united states abroad us federal california income tax purposes statute limitations remains open years inception due utilization net operating losses related prior years income tax returns audited federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions table contents differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions record liabilities related uncertain tax positions based upon fin believe currently pending items material adverse effect consolidated financial statements although adverse resolution several items period could material impact results operations period prior adoption fin recorded liabilities related uncertain tax positions based upon sfas accounting contingencies stockbased compensation december fasb issued sfas revised sharebased payment sfas r requires sharebased payments employees directors including grants stock options recognized statement operations based fair values sfas r supersedes accounting principles board opinion accounting stock issued employees apb amends sfas statement cash flows january adopted sfas r using modified prospective method adoption permitted sfas r requires compensation expense recorded nonvested stock options stockbased awards beginning first quarter adoption connection adoption sfas r refined valuation assumptions methodologies used derive assumptions however elected continue using blackscholes option valuation model fair value stock options granted prior adoption sfas r calculated using multiple option approach fair value stock options granted beginning january calculated using single option approach concurrent adoption sfas r determined blend historical volatility along implied volatility traded options stock would better measure market conditions expected volatility previously used historical stock price volatility reliable source volatility data estimate weightedaverage expected term stock options based historical cancellation exercise data related stock options well contractual term vesting terms awards record stockbased compensation expense using graded vesting expense attribution approach nonvested stock options granted prior adoption sfas r consistent expense attribution approach used historical sfas disclosures use straightline expense attribution approach stock options granted adoption sfas r currently believe straightline expense attribution approach better reflects level service provided employees vesting period awards stockbased compensation expense related stock options recognized net estimated forfeitures estimate forfeitures based historical experience result adoption sfas r recognize tax benefit stockbased compensation additional paidincapital apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements operations rather apic years ended december recognized stockbased compensation expense million million million respectively operating expenses capitalized million million million respectively inventory december unrecognized stockbased compensation million related nonvested stock options expect expense estimated weightedaverage period years management discussed development selection disclosure critical accounting policies audit committee board directors audit committee reviewed disclosure presented relating critical accounting policies table contents results operations total revenues total revenues billion billion billion included total revenues product sales royalty revenues contract revenues product sales product sales last three years consisted following thousands change change antiviral products truvada atripla viread hepsera emtriva total antiviral products ambisome letairis total product sales total product sales increased compared due primarily overall increase antiviral product sales including strong growth atripla sales well continued growth truvada sales foreign currency denominated product sales experienced net benefit depreciation us dollar approximately million compared total product sales increased compared due primarily increase total product sales volume billion favorable foreign currency exchange impact million significant percentage product sales continued denominated foreign currencies used foreign currency forward option contracts hedge percentage forecasted international sales primarily denominated euro reduced eliminate fluctuations sales due changes foreign currency exchange rates seen net benefit mentioned antiviral products antiviral product sales increased compared compared driven primarily sales volume growth atripla truvada well favorable foreign currency exchange impact truvada truvada sales increased compared driven primarily sales volume growth united states europe favorable foreign currency exchange impact truvada sales increased compared driven primarily strong sales volume growth europe well favorable foreign currency exchange environment truvada sales accounted total antiviral product sales respectively atripla atripla sales increased compared driven primarily continued uptake atripla united states well launches product european countries atripla sales increased compared due primarily first full year atripla sales table contents atripla launched united states july well continued strong uptake atripla united states consolidate atripla product sales primary beneficiary joint venture bristol myerssquibb company bms united states outside united states also recognize atripla product sales efavirenz portion atripla sales approximately million million million respectively atripla sales accounted total antiviral product sales respectively sales atripla european union significant atripla approved sale european union december antiviral products antiviral product sales include product sales viread hepsera emtriva increased compared driven primarily increase hepsera sales benefited favorable foreign currency impact well sales volume growth certain european countries antiviral product sales decreased compared driven primarily decrease sales viread emtriva respectively due impact patients switching viread emtriva containing regimens regimens containing truvada andor atripla countries combination products available partially offset increase hepsera sales due primarily sales volume growth across major geographical regions favorable foreign currency exchange environment ambisome sales ambisome increased compared due primarily favorable foreign currency exchange impact sales volume growth certain european markets sales ambisome increased compared due primarily sales volume growth europe well favorable foreign currency exchange impact ambisome product sales united states relate solely sales ambisome astellas pharma inc recorded manufacturing cost letairis sales letairis treatment pah increased compared driven primarily sales volume growth united states letairis launched june expect total product sales continue grow continue expand sales marketing efforts royalty revenues following table summarizes period period changes royalty revenues thousands change change royalty revenues significant source royalty revenues sales tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche royalty revenues million decrease compared driven primarily recognition tamiflu royalties roche million compared tamiflu royalties roche million lower tamiflu royalties due primarily decreased roche sales related pandemic planning initiatives worldwide royalty revenues million increase compared driven primarily recognition higher tamiflu royalties roche compared million recorded higher tamiflu royalties due table contents higher tamiflu sales recorded roche including sales related pandemic planning initiatives worldwide recognize royalties tamiflu sales roche quarter following quarter tamiflu sold cost goods sold product gross margin following table summarizes period period changes product sales thousands cost goods sold thousands product gross margin change change total product sales cost goods sold product gross margin product gross margin compared decreases product gross margin due primarily growing proportion atripla sales include efavirenz portion zero product gross margin impact changes product geographic mix product sales higher mix atripla product sales decreases overall product gross margin although record atripla product sales benefit product gross margin truvada portion atripla sales efavirenz portion atripla sales carries zero product gross profit gross margin since purchase efavirenz bms bmss net selling price efavirenz expect product gross margin lower compared due primarily higher expected atripla sales research development expenses following table summarizes period period changes major components rd expenses thousands change change research clinical development pharmaceutical development total research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed cros materials supplies license fees overhead allocations consisting various support facilities related costs rd activities separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology costs clinical development costs include costs phase clinical trials pharmaceutical development expenses consist costs product formulation chemical analysis rd expenses increased million compared due primarily increased clinical study expenses million primarily antiviral cardiovascular areas well increased compensation benefit expenses million due primarily higher headcount rd expenses increased million compared due primarily increased compensation benefit expenses million due largely higher headcount increased clinical study table contents expenses million increased contract service expenses million relating clinical product development research activities cardiovascular programs addition paid million upfront license fee lg life sciences ltd lgls million license related fee pari gmbh pari expensed future alternative uses technologies general significant collaboration payments like made lgls pari cause rd expenses fluctuate period period expect rd expenses increase levels due increased spending internal collaborative rd efforts anticipate progressing product candidates advanced clinical studies well adding clinical development programs pipeline selling general administrative expenses following table summarizes period period changes sga expenses last three years thousands change change selling general administrative sga expenses increased million compared due primarily increased compensation benefit expenses million due largely higher headcount increased marketing promotional expenses million support expanded commercial operations increased consulting support services expenses million related growth business costs million associated certain employee termination related disputes international operations well increased infrastructure technology expenses million increase compared partially offset decrease stockbased compensation expense million due primarily higher expense associated unvested stock options assumed myogen including accelerated stockbased compensation expenses related certain myogen employee terminations sga expenses increased million compared increase due primarily increase compensation benefits expenses million due largely higher headcount well increase marketing promotional expenses million antiviral cardiovascular areas including related launch letairis treatment pah expect sga expenses remain essentially consistent sga expenses believe organizational geographic expansion activities provide appropriate infrastructure support business purchased inprocess research development expenses connection acquisitions myogen inc myogen corus pharma inc corus recorded purchased iprd expenses billion million respectively year ended december table contents purchased iprd expense myogen represented estimated fair value myogens incomplete rd programs yet reached technological feasibility alternative future uses acquisition date therefore expensed upon acquisition summary programs acquisition date updated subsequent changes status development follows estimated acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide propanoic phase clinical trials completed prior acidclass endothelin receptor antagonist acquisition date filed nda fda era treatment pah december june fda approved letairis treatment pah united states additionally march european medicines agency emea validated marketing authorization application ambrisentan treatment pah filed collaboration partner gsk april european commission granted gsk marketing authorization ambrisentan treatment pah marketed name volibris gsk darusentan orally active etaselective era phase clinical development acquisition treatment resistant hypertension date date filing estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated fair value purchased iprd using present value discount rate based estimated internal rate return myogens operations comparable estimated weightedaverage cost capital companies myogens profile represents rate market participants would use value purchased iprd compensated differing phases development ambrisentan darusentan probabilityadjusting estimation expected future cash flows associated program determined time present value expected future cash flows using discount rate projected cash flows ambrisentan darusentan programs based key assumptions estimates revenues operating profits related programs considering stages development time resources needed complete development approval related product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets purpose estimating fair value ambrisentan program estimated program approximately complete acquisition date based estimated time cost complete phase clinical trials completed acquisition date estimated would incur future rd costs approximately million million date acquisition including year commercialization expected occur material net cash inflows estimated begin ambrisentan assuming necessary regulatory approvals would received product would successfully commercialized date table contents purpose estimating fair value darusentan program estimated program approximately complete acquisition date based estimated time cost complete remaining efforts would include completion phase clinical development well preparing filing nda fda acquisition date estimated would incur future rd costs approximately million million date acquisition including year commercialization expected occur material net cash inflows estimated begin darusentan assuming necessary regulatory approvals would received product would successfully commercialized date remaining efforts completing darusentan iprd program consist primarily clinical trials cost length success extremely difficult predict obtaining necessary regulatory approvals numerous risks uncertainties exist could prevent completion development including possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain darusentan treatment resistant hypertension approved united states countries outside united states whether marketing approvals significant limitations use future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections darusentan may never successfully commercialized result may make strategic decision discontinue development darusentan example believe commercialization difficult relative opportunities pipeline program completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely successful completion project materialize estimated reasons among others actual results may vary significantly estimated results purchased iprd expense corus represented estimated fair value coruss incomplete aztreonam inhalation solution cf rd program yet reached technological feasibility alternative future use acquisition date therefore expensed upon acquisition description program acquisition date updated subsequent changes status development follows estimated acquisition date fair value program description status development millions aztreonam inhalation aztreonam formulation phase clinical trials acquisition date filed nda solution inhalation used fda november september received complete treatment cf gramnegative bacteria response letter fda informing us fda approve cause lung infections patients nda aztreonam inhalation solution treatment cf cf current form requesting conduct additional phase clinical study november filed request formal dispute resolution fda february response appeal fda notified us reiterating position need conduct another clinical study aztreonam inhalation solution resubmit nda also submitted marketing authorization application european union received notice acceptance priority review health canada approval canada still awaiting responses respective regulatory bodies table contents estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated fair value purchased iprd using present value discount rate based estimated internal rate return coruss operations comparable estimated weightedaverage cost capital companies coruss profile represents rate market participants would use value purchased iprd projected cash flows aztreonam inhalation solution program based key assumptions estimates revenues operating profits related program considering stage development time resources needed complete development approval related product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets coruss two early stage candidates included valuation purchased iprd early stage projects identifiable revenues expenses associated purpose estimating fair value aztreonam inhalation solution program estimated program approximately complete acquisition date based estimated time cost complete remaining efforts would include completion phase clinical development well preparing filing nda fda acquisition date estimated would incur future rd costs approximately million million date acquisition including year commercialization expected occur material net cash inflows estimated begin aztreonam inhalation solution program assuming necessary regulatory approvals would received product would successfully commercialized date remaining efforts completing coruss iprd program consist primarily clinical trials cost length success extremely difficult predict numerous risks uncertainties exist could prevent completion development including possibility unfavorable results clinical trial risk failing obtain fda regulatory body approvals certain aztreonam inhalation solution treatment cf approved united states countries outside united states whether marketing approvals significant limitations use aztreonam inhalation solution treatment cf may never successfully commercialized result may make strategic decision discontinue development aztreonam inhalation solution treatment cf example believe commercialization difficult relative opportunities pipeline program completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely successful completion project materialize estimated reasons among others actual results may vary significantly estimated results connection acquisition cicletanine assets navitas assets llc recorded purchased iprd expense million consider acquisition material transaction made disclosures regarding related purchased iprd interest income net recorded interest income net million million million respectively decrease compared due primarily increased costs related hedging activities million net foreign currency losses million decreased interest income million due primarily lower interest rates partially offset writedowns certain securities recorded mentioned decrease compared primarily attributable lower average cash investment balances well writedown million million relating otherthantemporary impairment investments achillion pharmaceuticals inc assetbacked commercial paper structured investment vehicle respectively table contents provision income taxes provision income taxes million million million respectively effective tax rate differs us federal statutory rate due primarily tax credits resolution certain tax positions taxing authorities certain operating earnings nonus subsidiaries considered indefinitely invested outside united states offset state taxes effective tax rate differs us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely invested outside united states offset state taxes included operating income pretax charges million billion purchased iprd expenses associated corus myogen acquisitions respectively record income tax benefit related purchased iprd expenses amounts nondeductible effective tax rate differs us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely invested outside united states offset federal tax nondeductible purchased iprd expenses state taxes june fasb issued fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return fin also provides guidance derecognition classification interest penalties accounting interim periods disclosure transition fin effective fiscal years beginning december january adopted fin increased liability unrecognized tax benefits million corresponding charge opening balance accumulated deficit permitted fin addition reclassified million unrecognized tax benefits shortterm income taxes payable noncurrent deferred tax assets longterm income taxes payable date adoption total federal state foreign unrecognized tax benefits million recorded primarily longterm income taxes payable consolidated balance sheet including accrued liabilities related interest million total unrecognized tax benefits million recognized would reduced effective tax rate period recognition permitted provisions fin continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements operations december total federal state foreign unrecognized tax benefits million million respectively including interest million million respectively total unrecognized tax benefits december million million respectively recognized would reduce effective tax rate period recognition reached agreement irs several issues related examinations federal income tax returns result reduced unrecognized tax benefits million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs around certain uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective taxing authorities table contents liquidity capital resources following table summarizes cash cash equivalents marketable securities working capital cash flow activities end last three years thousands december cash cash equivalents marketable securities working capital year ended december cash provided used operating activities investing activities financing activities cash cash equivalents marketable securities cash cash equivalents marketable securities totaled billion december increase million december increase primarily attributable net cash provided operations billion proceeds issuances common stock employee stock plans million increases partially offset repurchases billion common stock stock repurchase program cash cash equivalents marketable securities totaled billion december increase billion december increase billion primarily attributable net cash provided operations billion proceeds issuances stock employee stock plans million increases partially offset repurchases million common stock stock repurchase programs repayment remaining amounts due term loan million capital expenditures million relating expansion facilities accommodate growth working capital working capital december billion increase million december increase primarily attributable increase million inventories due primarily purchases efavirenz estimated market value efavirenz bms increase million accounts receivable net driven primarily increased product sales million increase cash cash equivalents shortterm marketable securities increases partially offset million increase accounts payable due primarily purchases efavirenz estimated market value sustiva bms table contents working capital december billion compared billion december significant factors resulted increase working capital million increase cash cash equivalents shortterm marketable securities due primarily cash provided operating activities proceeds issuances common stock employee stock plans partially offset repurchases common stock stock repurchase program repayment term loan capital spending million increase prepaid taxes related intercompany profits us parent company joint venture million increase accounts receivable net due primarily increased sales cash provided operating activities cash provided operating activities billion primarily related net income billion adjusted noncash items million tax benefits employee stock plans million stockbased compensation expense partially offset million excess tax benefits stock option exercises reclassified cash provided financing activities accordance sfas r million cash outflow related changes operating assets liabilities cash provided operating activities billion comprised primarily billion net income adjusted noncash items million stockbased compensation expense million deferred income taxes million tax benefits related employee stock plans million excess tax benefits stock option exercises partially offset million net cash outflow related changes operating assets liabilities cash provided operating activities billion comprised primarily billion net loss adjusted noncash items billion purchased iprd expense stockbased compensation expense million million tax benefits related employee stock plans million excess tax benefits stock option exercises partially offset million net cash outflow related changes operating assets liabilities cash used investing activities cash used investing activities primarily related purchases sales maturities availableforsale securities well capital expenditures cash used investing activities primarily related purchases sales maturities availableforsale securities capital expenditures acquisition nycomed limited cash used investing activities primarily related purchases sales maturities availableforsale securities acquisitions myogen raylo chemicals inc raylo corus well capital expenditures used million cash investing activities compared billion decrease due primarily cash used financing activities compared fund stock repurchases used billion cash investing activities compared billion decrease million decrease due primarily acquisitions myogen raylo corus total billion well cash used purchases sales maturities marketable securities activities compared capital expenditures made related primarily expansion manufacturing capabilities upgrades facilities spending computer laboratory equipment well enterprise table contents software accommodate continued business growth capital expenditures also included construction new building foster city california headquarters capital expenditures also included purchase two buildings previously leased well construction costs new building foster city california headquarters december capital expenditure commitments million included purchase office building land well three aircraft constructed delivery discussed expect fulfill commitments funds generated operating cash flows october signed purchase sale agreement purchase office building approximately acres land located foster city california aggregate purchase price approximately million made initial refundable deposit million escrow october january remaining balance million paid escrow upon closing transaction part closing purchase sale agreement amended allow holdback escrow million purchase price released depending outcome certain requirements mutually agreed closing august result review terms existing corporate aircraft leases upon consideration various alternatives available us upon expiration entered agreements purchase three aircraft constructed delivery aggregate purchase price purchase agreements million december made deposits totaling million recorded noncurrent assets consolidated balance sheet future deposits due terms purchase agreements follows million million million million million option terminate purchase agreements subject maximum payment fully equipped price aircraft cash provided used financing activities cash used financing activities billion driven primarily billion used repurchase common stock stock repurchase program cash outflows partially offset proceeds million received issuances common stock employee stock plans well million excess tax benefits stock option exercises october board authorized program repurchase common stock aggregate amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means stock repurchase program expires december stock repurchase program repurchased shares open market also entered two structured accelerated share repurchase transactions third parties described february entered accelerated share repurchase agreement financial institution repurchase million common stock accelerated basis terms accelerated share repurchase agreement financial institution paid million financial institution settle initial purchase transaction received shares common stock price per share june upon maturity agreement accordance share delivery provisions agreement received additional shares common stock based average daily volume weightedaverage prices common stock specified period less predetermined discount per share result final purchase price common stock accelerated share repurchase per share october entered accelerated share repurchase transaction financial institution repurchase million common stock accelerated basis terms accelerated share repurchase agreement financial institution paid million financial institution settle initial purchase transaction received shares common stock price per share april subject extension certain circumstances well maximum minimum share delivery provisions agreement may receive additional shares financial institution depending average daily volume weightedaverage prices common stock table contents specified period less predetermined discount per share making initial payment million obligated deliver cash shares financial institution except certain limited circumstances case method delivery cash shares common stock would discretion december remaining authorized amount stock repurchases may made stock repurchase program expires december million cash used financing activities million driven primarily million used repurchase common stock stock repurchase program million used pay remaining amounts due term loan partially offset proceeds issuance stock employee stock plans million well million excess tax benefits stock option exercises cash provided financing activities million driven primarily million net proceeds generated issuance convertible senior notes due notes convertible senior notes due notes collectively notes related transactions addition received proceeds issuance stock employee stock plans million well million excess tax benefits employee stock option exercises cash inflows partially offset million principal repayments term loan information december along whollyowned subsidiary gilead biopharmaceutics ireland corporation gbic entered amended restated credit agreement superseded existing revolving credit agreement syndicate banks increase credit facility billion amended restated credit agreement also includes subfacility swingline loans letters credit terms amended restated credit agreement may borrow initially aggregate billion revolving credit loans loans amended restated credit agreement bear interest either libor plus margin ranging basis points basis points ii base rate defined amended restated credit agreement prepay outstanding borrowings time whole part without penalty premium outstanding interest principal would due payable december connection amended restated credit agreement entered parent guaranty agreement guaranteed obligations gbic amended restated credit agreement expect use proceeds loans amended restated credit agreement working capital requirements general corporate purposes december million letter credit outstanding amended restated credit agreement believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products establishment additional collaborative relationships companies costs associated defense settlement adverse results litigation government investigations table contents may future require additional funding could form proceeds equity debt financings funding required assure available us favorable terms balance sheet arrangements balance sheet arrangements currently material reasonably likely material consolidated financial position results operations contractual obligations contractual obligations consist debt obligations operating leases well purchase obligations primarily form capital commitments purchase obligations active pharmaceutical ingredients inventory related items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact certain obligations may cancelable december thousands payments due period less one contractual obligations total year years years years convertible senior notes operating lease obligations capital commitments purchase obligations clinical trials total december outstanding principal billion notes issued april december firm capital project commitments approximately million primarily relating expansion facilities infrastructure well purchase commitments three corporate aircraft constructed delivery december firm purchase commitments related active pharmaceutical ingredients certain inventory related items amounts related active pharmaceutical ingredients represent minimum purchase requirements actual purchases expected significantly exceed amounts addition committed make potential future milestone payments third parties part licensing development programs payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheet included table december several clinical studies various clinical trial phases significant clinical trial expenditures cros although contracts cros cancelable generally cancelled contracts amounts reflect commitments based existing contracts reflect future modifications termination existing contracts anticipated potential new contracts total gross unrecognized tax benefit liabilities million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs around certain uncertain tax table contents positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective taxing authorities amounts included longterm income taxes payable longterm deferred tax assets consolidated balance sheet included table recent accounting pronouncements june fasb ratified eitf issue determining whether instrument embedded feature indexed entitys stock eitf eitf provides guidance determine certain instruments embedded features considered indexed stock including instruments similar notes convertible note hedges warrants purchase stock forward contract entered part accelerated share repurchase transaction february completed june forward contract entered part accelerated share repurchase transaction october eitf requires companies use twostep approach evaluate instruments contingent exercise provisions settlement provisions determining whether instrument considered indexed stock exempt application sfas accounting derivative instruments hedging activities although eitf effective fiscal years beginning december outstanding instrument date adoption require retrospective application accounting cumulative effect adjustment retained earnings upon adoption expect adoption eitf material impact consolidated financial position results operations may fasb issued fsp apb accounting convertible debt instruments may settled cash upon conversion including partial cash settlement fsp apb fsp apb addresses instruments commonly referred instrument c eitf requires issuer settle principal amount cash conversion spread cash net shares issuers option fsp apb requires issuers instruments account liability equity components separately bifurcating conversion option debt instrument classifying conversion option equity accreting resulting discount debt additional interest expense expected life debt fsp apb effective fiscal years beginning december interim periods within fiscal years requires retrospective application periods presented early application permitted expect adoption fsp apb material impact consolidated financial position results operations based requirements fsp apb estimate fsp apb effective current comparative periods would reported additional interest expense related notes approximately million million million respectively december fasb issued sfas noncontrolling interests consolidated financial statements amendment accounting research bulletin consolidated financial statements sfas sfas establishes accounting reporting standards ownership interests subsidiaries held parties parent amount consolidated net income loss attributable parent noncontrolling interests changes parents ownership interest valuation retained noncontrolling equity investments subsidiary deconsolidated sfas also establishes additional reporting requirements identify distinguish ownership interest parent interest noncontrolling owners sfas effective interim periods fiscal years beginning december upon adopting sfas plan reclassify noncontrolling interest minority interest consolidated balance sheets liabilities stockholders equity present noncontrolling interest minority interest consolidated statements operations net income attributable noncontrolling interest component total consolidated net income loss december fasb issued sfas revised business combinations sfas r sfas r establishes principles requirements recognizing measuring assets acquired liabilities assumed noncontrolling interests acquiree business combination sfas r also provides table contents guidance recognizing measuring goodwill acquired business combination requires purchased iprd capitalized fair value intangible assets time acquisition requires acquisitionrelated expenses restructuring costs recognized separately business combination expands definition constitutes business requires acquirer disclose information users may need evaluate understand financial effect business combination sfas r effective prospective basis impact business combination transactions acquisition date occurs december depending nature magnitude future business combination transactions sfas r may material impact consolidated financial position andor results operations item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business significant percentage product sales denominated foreign currencies enter foreign currency exchange forward contracts foreign currency exchange option contracts partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged recent years foreign currency exchange fluctuations primarily positive impact product sales gross margin however full impact foreign currency fluctuations moderated hedging program table contents following table summarizes notional amounts weightedaverage currency exchange rates fair values open foreign currency exchange forward option contracts december contracts maturities months less weightedaverage rates stated terms amount us dollars per foreign currency fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands foreign currency exchange forward contracts weighted average notional settlement currency amount price fair value euro british pound australian dollar danish krone norwegian krone swiss franc total foreign currency exchange option contracts weighted average notional strike currency amount price fair value british pound euro australian dollar total total foreign exchange forward option contracts total notional amount billion total fair value relating net asset million open foreign currency exchange forward option contracts december compares total notional amount billion total fair value relating net liability million open foreign currency exchange forward contracts december interest rate risk portfolio availableforsale marketable securities fixed variable rate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based duration industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return table contents following table summarizes expected maturities average interest rates interest generating assets interestbearing liabilities december dollars thousands years ending december total fair value december thereafter assets availableforsale debt securities average interest rate liabilities convertible senior notes average interest rate april issued million principal amount convertible senior notes due notes million principal amount convertible senior notes due notes private placement pursuant rule securities act amended notes notes issued par bear interest rates respectively may converted subject certain circumstances credit risk portion marketable securities held auction rate securities began observing failed auctions auction rate securities whose underlying assets comprised student loans december held approximately million auction rate securities within availablefor sale longterm marketable securities whose underlying assets comprised student loans auction rate securities comprised approximately total cash cash equivalents marketable securities december auction rate securities including subject failed auctions currently rated aaa consistent high quality rating required investment policy auctions continue fail securities invested may unable liquidate auction rate securities par need desire access funds invested securities however believe based total cash marketable securities position expected operating cash flows well access funds credit facility able hold securities recovery auction market may final maturity result anticipate current illiquidity auction rate securities material effect cash requirements working capital light volatility developments seen financial markets continued review cash equivalents marketable securities carefully well invest prudently believe maintaining primary goals investment policy safety preservation principal diversification risk well liquidity investments sufficient meet cash flow requirements protected us much risks credit markets allowing us continue meet operating cash flow requirements well execute opportunities million million accelerated share repurchases accounts receivable balance december billion compared million december growth accounts receivable balances due primarily higher product sales antiviral products united states europe european product sales government owned supported customers greece italy portugal spain subject significant payment delays due government funding reimbursement practices resulted may continue result increase days sales outstanding due average length time accounts receivable outstanding turn may increase credit risk related certain customers sales customers countries europe tend pay relatively slowly increased may continue increase average length time accounts receivable outstanding december accounts receivable greece italy portugal spain totaled million million days past due table contents date experienced significant losses respect collection accounts receivable believe substantially accounts receivable balances collectible perform credit evaluations customers financial condition generally required collateral item financial statements supplementary data financial statements required item set forth beginning report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined securities exchange sec rules controls procedures company designed ensure information required disclosed company reports files submits securities exchange act amended exchange act recorded processed summarized reported within time periods specified secs rules forms based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined exchange act rule af internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included annual report issued report effectiveness internal control financial reporting december report audit internal control financial reporting appears table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited gilead sciences incs internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso criteria gilead sciences incs management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated financial statements gilead sciences inc report dated february expressed unqualified opinion thereon ernst young llp palo alto california february table contents c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting stockholders proxy statement headings nominees board committees meetings executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance changes waivers code ethics disclosed website intend satisfy disclosure requirement item form k regarding amendment waiver provision code ethics disclosing information website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee interlocks insider participation compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference section proxy statement headings security ownership certain beneficial owners management securities authorized issuance equity compensation plans item certain relationships related transactions director independence information required item incorporated reference section proxy statement headings nominees certain relationships related party transactions item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services table contents part iv item exhibits financial statement schedules following documents filed part annual report index list consolidated financial statements report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document restated certificate incorporation registrant certificate designation series junior participating preferred stock registrant certificate amendment certificate designation series junior participating preferred stock registrant amended restated bylaws registrant amended restated october reference made exhibit exhibit exhibit exhibit amended restated rights agreement registrant chasemellon shareholder services llc dated october first amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated october second amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated may indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april table contents exhibit exhibit footnote number description document confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring amended restated credit agreement among registrant gilead biopharmaceutics ireland corporation lenders parties thereto bank america na administrative agent swing line lender lc issuer dated december parent guaranty agreement dated december registrant master confirmation registrant citibank na together supplemental confirmation dated october gilead sciences inc stock option plan amended january form option agreements used stock option plan gilead sciences inc nonemployee directors stock option plan amended january form option agreement used gilead sciences inc nonemployee directors stock option plan gilead sciences inc equity incentive plan amended may form employee stock option agreement used equity incentive plan grants prior february form employee stock option agreement used equity incentive plan grants commencing february form nonemployee director stock option agreement used equity incentive plan grants prior form nonemployee director option agreement used equity incentive plan initial grants commencing form nonemployee director option agreement used equity incentive plan annual grants commencing may form performance share award agreement used equity incentive plan grants form performance share award agreement used equity incentive plan grants commencing form restricted award agreement used equity incentive plan grants prior form restricted stock unit issuance agreement used equity incentive plan grants commencing table contents exhibit exhibit footnote number description document gilead sciences inc employee stock purchase plan amended may gilead sciences inc deferred compensation planbasic plan document gilead sciences inc deferred compensation planadoption agreement addendum gilead sciences inc deferred compensation plan gilead sciences inc deferred compensation plan amended restated october gilead sciences inc severance plan amended december gilead sciences inc corporate bonus plan gilead sciences inc code section bonus plan base salaries named executive officers offer letter dated october registrant caroline dorsa offer letter dated april registrant robin washington form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees form employee proprietary information invention agreement entered registrant certain officers key employees revised september amended restated collaboration agreement among registrant gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated september commercialization agreement gilead sciences limited bristolmyers squibb company dated december letter agreement registrant institute organic chemistry biochemistry academy sciences czech republic iocb rega stichting vzw rega together iocb iocbrega dated september amendment agreement registrant iocbrega dated october amendment agreement registrant iocbrega dated december sixth amendment agreement license agreement iocb k u leuven research development registrant dated august development license agreement among registrant f hoffmannla roche ltd hoffmannla roche inc dated september first amendment supplement dated november development licensing agreement registrant f hoffmann la roche ltd hoffmanla roche inc dated september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may royalty sale agreement among registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july table contents exhibit exhibit footnote number description document amended restated license agreement registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july license agreement japan tobacco inc registrant dated march license agreement registrant successor myogen inc abbott deutschland holding gmbh dated october license agreement registrant successor myogen inc abbott laboratories dated june master clinical commercial supply agreement gilead world markets limited registrant patheon inc dated january tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated july addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated may addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated december tenofovir disoproxil fumarate manufacturing supply agreement registrant ampac fine chemicals llc dated march restated amended toll manufacturing agreement gilead sciences limited registrant altana pharma oranienburg gmbh dated november emtricitabine manufacturing supply agreement gilead sciences limited degussa ag dated june purchase sale agreement escrow instructions electronics imaging inc registrant dated october amended subsidiaries registrant consent independent registered public accounting firm power attorney reference made signature certification chief executive officer required rule aa rule da securities exchange act amended certification chief financial officer required rule aa rule da securities exchange act amended certifications chief executive officer chief financial officer required rule ab rule db section chapter title united states code usc filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form k filed november incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference table contents filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form filed june incorporated herein reference filed exhibit registrants current report form k filed april incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants current report form k also filed december incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants current report form ka filed february incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants current report form k first filed december incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference information included registrants current report form k filed january incorporated herein reference filed exhibit registrants annual report fiscal year ended march incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form qa filed november incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit myogen incs registration statement form amended originally filed august incorporated herein reference table contents filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed august incorporated herein reference management contract compensatory plan arrangement certification accompanies relates deemed filed securities exchange commission incorporated reference filing registrant securities act amended securities exchange act amended whether made date irrespective general incorporation language contained filing certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrants application requesting confidential treatment rule b securities exchange act amended table contents gilead sciences inc consolidated financial statements years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements schedule responsibility companys management responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein also audited accordance standards public company accounting oversight board united states gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion thereon ernst young llp palo alto california february table contents gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid taxes prepaid expenses current assets total current assets property plant equipment net noncurrent portion prepaid royalties noncurrent deferred tax assets longterm marketable securities noncurrent assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued compensation employee benefits accrued royalties income taxes payable accrued liabilities deferred revenues current portion longterm obligations total current liabilities longterm deferred revenues convertible senior notes longterm income taxes payable longterm obligations minority interest commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december respectively additional paidin capital accumulated comprehensive income loss retained earnings total stockholders equity total liabilities stockholders equity see accompanying notes table contents gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales royalty revenues contract revenues total revenues costs expenses cost goods sold research development selling general administrative purchased inprocess research development total costs expenses income loss operations interest income net interest expense minority interest income loss provision income taxes provision income taxes net income loss net income loss per sharebasic shares used per share calculationbasic net income loss per sharediluted shares used per share calculationdiluted see accompanying notes table contents gilead sciences inc consolidated statement stockholders equity thousands common stock accumulated retained additional deferred earnings total paidin comprehensive stock accumulated stockholders shares amount capital income loss compensation deficit equity balance december net loss unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive loss issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans reversal deferred stock compensation compensatory stock transactions assumption stock options connection acquisitions purchase convertible note hedges sale warrants deferred tax assets convertible note hedges repurchases common stock balance december adoption fin accounting uncertainty income taxes net income unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans compensatory stock transactions repurchases common stock balance december net income unrealized loss availableforsale securities net tax foreign currency translation adjustment unrealized gain cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans compensatory stock transactions repurchases common stock balance december see accompanying notes table contents gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income loss adjustments reconcile net income loss net cash provided operating activities depreciation amortization purchased inprocess research development stockbased compensation expense excess tax benefits stockbased compensation tax benefits employee stock plans deferred income taxes noncash transactions changes operating assets liabilities accounts receivable net inventories prepaid expenses assets accounts payable income taxes payable accrued liabilities deferred revenues minority interest net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities acquisitions net cash acquired purchases nonmarketable equity securities capital expenditures net cash used investing activities financing activities proceeds issuances common stock proceeds issuance convertible senior notes net issuance costs proceeds sale warrants purchases convertible note hedges repurchases common stock repayments longterm debt obligations excess tax benefits stockbased compensation net cash provided used financing activities effect exchange rate changes cash net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid income taxes paid noncash investing financing activities reclassification achillion equity investment noncurrent assets marketable securities upon achillions initial public offering see accompanying notes table contents gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering life threatening diseases worldwide headquartered foster city california operations north america europe australia date focused efforts bringing novel therapeutics treatment life threatening diseases market currently market truvada emtricitabine tenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil viread treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment severe fungal infection letairis ambrisentan treatment pulmonary arterial hypertension pah vistide cidofovir injection treatment cytomegalovirus infection flolan epoprostenol sodium treatment pulmonary hypertension f hoffmanla roche ltd together hoffmanla roche inc roche markets tamiflu oseltamivir phosphate treatment influenza royalty paying collaborative agreement us perform manufacturing activities macugen pegaptamib sodium injection manufacturing agreement osi pharmaceuticals inc osi sells macugen treatment neovascular agerelated macular degeneration royalty paying collaborative agreement us basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries joint ventures bristol myers squibb company bms primary beneficiary determined financial accounting standards board fasb interpretation revised december consolidation variable interest entities fin r record minority interest consolidated financial statements reflect bmss interest joint ventures significant intercompany transactions eliminated consolidated financial statements include results companies acquired us date acquisition significant accounting policies estimates judgments preparation consolidated financial statements conformity united states generally accepted accounting principles requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis management evaluates estimates including critical accounting policies estimates related revenue recognition allowance doubtful accounts prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition product sales recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured upon table contents gilead sciences inc notes consolidated financial statementscontinued recognition revenue product sales provisions made government rebates customer incentives cash discounts prompt payment certain distributor fees estimated future returns products may expire appropriate items deducted gross product sales government rebates estimate amounts payable us government managed medicaid programs well certain qualifying federal state foreign government programs based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements government rebates invoiced directly us recorded accrued liabilities consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable cash discounts estimate cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales product returns provide customers general right product return permit returns product damaged defective received customer case product sold unites states product expired accept product returns united states expired one year expiration dates estimates expected returns expired products based primarily ongoing analysis historical return patterns royalty revenues royalty revenue distributor sales ambisome recognized month following month corresponding sales occur royalty revenue sales products generally recognized received generally quarter following quarter corresponding sales occur contract revenues revenue nonrefundable upfront license fees milestone payments continue obligations development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms gileads table contents gilead sciences inc notes consolidated financial statementscontinued obligations types arrangements revenue recognized obligation fulfilled ratably development manufacturing period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue consolidated balance sheets contract revenues include net revenue product distribution services recognized persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured accordance emerging issues task force eitf issue reporting revenue gross principal versus net agent record product distribution services revenue net supply price paid manufacturerlicensor distribution fees paid specialty pharmacies allowances product returns cash discounts government rebates contract revenues consolidated statements operations shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements operations research development expenses major components research development rd expenses consist personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies licenses fees overhead allocations consisting various support facilities related costs rd activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology costs clinical development costs include costs phase clinical trials pharmaceutical development costs consist expenses incurred connection product formulation chemical analysis charge rd costs including clinical study costs expense incurred consistent statement financial accounting standards sfas accounting research development costs clinical study costs significant component rd expenses clinical studies performed third party cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies reflect level effort expended cro material cro contracts terminable us upon written notice generally liable actual effort expended cro certain noncancelable expenses incurred point termination amounts paid advance related incomplete services refunded contract terminated contracts include additional termination payments become due payable terminate contract additional termination payments recorded contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million net income loss per share basic net income loss per share calculated based weightedaverage number shares common stock outstanding period diluted net income loss per share calculated based table contents gilead sciences inc notes consolidated financial statementscontinued weightedaverage number shares common stock outstanding dilutive securities outstanding period potential dilutive shares common stock resulting assumed exercise outstanding stock options equivalents consisting primarily performance shares assumed exercise warrants relating convertible senior notes due notes convertible senior notes due notes collectively notes determined treasury stock method notes considered instrument c securities defined eitf issue convertible bonds issuer option settle cash upon conversion eitf therefore conversion spread relating notes included diluted net income loss per share calculation potential dilutive shares common stock resulting assumed settlement conversion spread notes determined method set forth eitf method settlement conversion spread notes dilutive effect average market price common stock period exceeds notes notes respectively average market price common stock year ended december exceed conversion prices notes years ended average market price common stock exceeded conversion price either notes dilutive effect included table warrants relating notes notes dilutive effect average market price common stock period exceeds warrants exercise prices respectively average market price common stock years ended december exceed warrants exercise prices relating notes stock options purchase approximately million million weightedaverage shares common stock outstanding years ended december respectively included computation diluted net income per share options exercise prices greater average market price common stock periods therefore effect antidilutive due net loss approximately million weightedaverage number outstanding stock options common stock equivalents included computation diluted net loss per share inclusion would antidilutive following table reconciliation numerator denominator used calculation basic diluted net income loss per share thousands year ended december numerator net income loss denominator weightedaverage shares common stock outstanding used calculation basic net income loss per share effect dilutive securities stock options equivalents conversion spread related convertible senior notes conversion spread related convertible senior notes weightedaverage shares common stock outstanding used calculation diluted net income loss per share table contents gilead sciences inc notes consolidated financial statementscontinued stockbased compensation january adopted provisions sfas revised sharebased payment sfas r requires sharebased payments employees directors including grants stock options recognized consolidated statements operations based fair values sfas r also requires benefit tax deductions excess recognized compensation cost reported consolidated statements cash flows financing activity rather operating activity applied modified prospective method requires compensation expense recorded vesting nonvested stock options stockbased awards beginning first quarter adoption sfas r addition calculated pool excess tax benefits available within additional paidin capital apic accordance provisions sfas r cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents may enter overnight repurchase agreements repos purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold us eligible instruments investment policy included cash equivalents include commercial paper money market funds bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist primarily debt securities include auction rate securities variable rate demand obligations time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported either cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale securities excluded net income loss reported accumulated comprehensive income loss separate component stockholders equity interest income net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position well severity duration unrealized losses determine decline fair value investment accounting basis decline otherthan temporary reduce carrying value security hold record loss amount decline result entering collaborations time time may hold investments nonpublic companies record nonmarketable securities cost noncurrent assets less amounts otherthantemporary impairment regularly review investments indicators impairment investments nonmarketable securities material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities duration industry group investment type table contents gilead sciences inc notes consolidated financial statementscontinued issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe certain countries payments typically slow primarily greece italy portugal spain aggregated accounts receivable balances significant cases slow payment practices countries reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries europe tend pay relatively slowly increased may continue increase average length time accounts receivable outstanding december accounts receivable greece italy portugal spain totaled million million days past due december accounts receivable countries totaled million million days past due date experienced significant losses respect collection accounts receivable believe past due accounts receivable net allowances reflected consolidated balance sheets collectible perform credit evaluations customers financial conditions generally required collateral certain raw materials utilize operations obtained single suppliers many raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application nda filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship products supply drug candidates clinical trials accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks government rebates cash discounts prompt payment doubtful accounts sales returns estimates wholesaler chargebacks government rebates cash discounts sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual obligations historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant consistent managements expectations inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventories order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized prepaid royalties prepaid royalties capitalized cost initially equivalent present value future royalty obligation would expect pay licensor expected levels product sales incorporating table contents gilead sciences inc notes consolidated financial statementscontinued related technology review quarterly expected future sales levels products indicators might require writedown net recoverable value change estimated life prepaid royalty amortize prepaid royalties cost goods sold remaining life underlying patent based effective royalty rate derived forecasted future product sales incorporating related technology review effective royalty rate least annually prospectively adjust effective rate based significant new facts circumstances may arise review prepaid royalties primarily comprised emtricitabine royalties paid emory university emory hiv indication royalty pharma purchased royalty interest owned emory terms transaction royalty pharma paid respectively total purchase price million emory exchange elimination emtricitabine royalties due emory worldwide net sales products containing emtricitabine result transaction capitalized prepaid royalties share million purchase price million december unamortized prepaid royalty asset million million million million amortized cost goods sold respectively property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method repairs maintenance costs expensed incurred estimated useful lives years follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term office computer equipment includes capitalized software capitalized software purchased internally developed software unamortized capitalized software costs million million consolidated balance sheet december respectively leasehold improvements capitalized leased equipment amortized shorter lease term assets useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction inprogress included property plant equipment interest capitalized significant goodwill intangible assets goodwill represents excess purchase price estimated fair value net assets acquired business combination accordance sfas goodwill intangible assets sfas goodwill amortized required tested annually impairment accordance sfas test goodwill impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount intangible assets definite lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable table contents gilead sciences inc notes consolidated financial statementscontinued impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment fda another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated income producing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset asset group eventual disposition carrying amount asset asset group estimating future cash flows assets liabilities grouped lowest level identifiable cash flows largely independent cash flows generated groups undiscounted future cash flows less carrying amount asset asset group impairment loss measured excess carrying value asset asset group estimated fair value recognized cash flow estimates used calculations based managements best estimates using appropriate customary assumptions projections time foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income loss recorded accumulated comprehensive income loss separate component stockholders equity net foreign currency exchange transaction gains losses included interest income net consolidated statements operations net transaction gains losses totaled million million million respectively hedge certain foreign currency exposures related outstanding monetary assets liabilities forecasted product sales foreign currency exchange forward contracts foreign currency exchange option contracts general market risks contracts offset corresponding gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time limit risk counterparties contracts may unable perform transacting major banks monitor closely context current market conditions also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter speculative foreign currency transactions hedge net investment foreign subsidiaries fair value financial instruments financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain noncurrent assets foreign currency exchange forward option contracts accounts payable longterm debt longterm obligations cash cash equivalents marketable securities see note foreign currency exchange contracts hedge accounts receivable see note reported respective fair values balance sheets foreign currency exchange contracts hedge forecasted sales recorded fair value net related deferred gain loss resulting reported net balance zero remaining financial instruments reported consolidated balance sheets amounts approximate current fair values table contents gilead sciences inc notes consolidated financial statementscontinued september fasb issued sfas fair value measurements sfas sfas defines fair value establishes framework measuring fair value expands disclosure requirements regarding fair value measurements sfas effective fiscal years beginning november financial assets liabilities well nonfinancial assets liabilities recognized disclosed fair value recurring basis financial statements accordance fasb staff position fsp fas effective date fasb statement nonfinancial assets liabilities sfas effective fiscal years beginning november october fasb issued fsp determining fair value financial asset market asset active fsp clarifies application sfas market active provides example illustrate key considerations determining fair value financial asset market financial asset active fsp applicable valuation auction rate securities held us active market december fsp effective upon issuance including prior periods financial statements issued january adopted provisions sfas prospective basis financial assets liabilities sfas requires determine fair value financial assets liabilities using fair value hierarchy established sfas describes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques well significant management judgment estimation adoption sfas fsp effect consolidated net income year ended december following table summarizes major category assets liabilities respective fair value classification level input within fair value hierarchy defined sfas thousands fair value measurement december using quoted prices active significant markets significant identical observable unobservable december assets inputs inputs level level level assets cash equivalents marketable securities derivatives liabilities derivatives table contents gilead sciences inc notes consolidated financial statementscontinued following table reconciliation marketable securities measured fair value using significant unobservable inputs level thousands year ended december balance beginning period total realized losses included interest income net total unrealized losses included comprehensive income sales marketable securities net purchases transfers level balance end period total losses year ended december included earnings attributable change unrealized losses relating assets still held reporting date reported interest income net marketable securities measured fair value using level inputs substantially comprised auction rate securities within availableforsale investment portfolio underlying assets auction rate securities comprised student loans although auction rate securities would typically measured using level inputs failure auctions lack market activity liquidity experienced since beginning required securities measured using level inputs fair value auction rate securities determined using discounted cash flow model considered projected cash flows issuing trusts underlying collateral expected yields projected cash flows estimated based underlying loan principal bonds outstanding payout formulas weightedaverage life cash flows projected considered collateral composition securities related historical projected prepayments underlying student loans weightedaverage useful life three nine years discount rates used discounted cash flow model based market conditions comparable similar term assetbacked securities well fixed income securities adjusted illiquidity discount resulting discount rate auction rate securities reset every seven days maturity dates ranging interest rates ranging december auction rate securities continued earn interest auction rate securities measured using level inputs recorded longterm marketable securities consolidated balance sheet december although failed auctions well lack market activity liquidity based assessment underlying collateral creditworthiness issuers securities ability intent hold securities anticipated recovery could final maturity otherthantemporary impairments securities december income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations existing tax laws regulations various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates accounting stock options sharebased payments mergers acquisitions future levels table contents gilead sciences inc notes consolidated financial statementscontinued rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pre tax earnings finalization federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact consolidated net income january adopted fasb interpretation accounting uncertainty income taxes fin interpretation sfas accounting income taxes sfas fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return fin also provides guidance derecognition classification interest penalties accounting interim periods disclosure transition result adoption fin increased liability unrecognized tax benefits million corresponding charge opening balance accumulated deficit permitted fin addition reclassified million unrecognized tax benefits shortterm income taxes payable noncurrent deferred tax assets longterm income taxes payable date adoption total federal state foreign unrecognized tax benefits million recorded primarily longterm income taxes payable consolidated balance sheet including accrued liabilities related interest million total unrecognized tax benefits million recognized would reduced effective tax rate period recognition permitted provisions fin continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements operations recent accounting pronouncements june fasb ratified eitf issue determining whether instrument embedded feature indexed entitys stock eitf eitf provides guidance determine certain instruments embedded features considered indexed stock including instruments similar notes convertible note hedges warrants purchase stock forward contract entered part accelerated share repurchase transaction february completed june forward contract entered part accelerated share repurchase transaction october eitf requires companies use twostep approach evaluate instruments contingent exercise provisions settlement provisions determining whether instrument considered indexed stock exempt application sfas accounting derivative instruments hedging activities although eitf effective fiscal years beginning december outstanding instrument date adoption require retrospective application accounting cumulative effect adjustment retained earnings upon adoption expect adoption eitf material impact consolidated financial position results operations may fasb issued fsp apb accounting convertible debt instruments may settled cash upon conversion including partial cash settlement fsp apb fsp apb addresses instruments commonly referred instrument c eitf requires issuer settle principal amount cash conversion spread cash net shares issuers option fsp apb requires issuers instruments account liability equity components separately bifurcating conversion option debt instrument classifying conversion option equity accreting resulting discount debt additional interest expense expected life debt fsp apb effective fiscal years beginning december interim periods within fiscal years requires retrospective application periods presented early application permitted expect adoption fsp apb material impact consolidated financial position table contents gilead sciences inc notes consolidated financial statementscontinued results operations based requirements fsp apb estimate fsp apb effective current comparative periods would reported additional interest expense related convertible senior notes approximately million million million respectively december fasb issued sfas noncontrolling interests consolidated financial statements amendment accounting research bulletin consolidated financial statements sfas sfas establishes accounting reporting standards ownership interests subsidiaries held parties parent amount consolidated net income loss attributable parent noncontrolling interests changes parents ownership interest valuation retained noncontrolling equity investments subsidiary deconsolidated sfas also establishes additional reporting requirements identify distinguish ownership interest parent interest noncontrolling owners sfas effective interim periods fiscal years beginning december upon adopting sfas plan reclassify noncontrolling interest minority interest consolidated balance sheets liabilities stockholders equity present noncontrolling interest minority interest consolidated statements operations net income attributable noncontrolling interest component total consolidated net income loss december fasb issued sfas revised business combinations sfas r sfas r establishes principles requirements recognizing measuring assets acquired liabilities assumed noncontrolling interests acquiree business combination sfas r also provides guidance recognizing measuring goodwill acquired business combination requires purchased inprocess research development iprd capitalized fair value intangible assets time acquisition requires acquisitionrelated expenses restructuring costs recognized separately business combination expands definition constitutes business requires acquirer disclose information users may need evaluate understand financial effect business combination sfas r effective prospective basis impact business combination transactions acquisition date occurs december depending nature magnitude future business combination transactions sfas r may material impact consolidated financial position andor results operations derivative financial instruments derivatives recognized either assets liabilities measured fair value based quoted market prices enter foreign currency forward contracts hedge changes fair value certain monetary assets liabilities denominated nonfunctional currency record changes fair value instruments interest income net derivative instruments designated hedges sfas nos accounting derivative instruments hedging activities collectively referred sfas enter foreign currency forward option contracts maturities months less hedge percentage future cash flows related forecasted product sales certain foreign currencies derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified hedges related forecasted foreign currency denominated product sales designated documented inception respective hedge designated cash flow hedges sfas evaluated effectiveness quarterly inception hedging relationship quarterly basis perform regression analysis taking change cash flow underlying contract regressing change cash flow hedge instrument excluding time value assess effectiveness hedging relationship assess hedge effectiveness retrospective basis using dollar offset approach table contents gilead sciences inc notes consolidated financial statementscontinued monthly exclude time value effectiveness testing recognize changes time value hedge interest income net excluded gains losses million million million assessment hedge effectiveness respectively effective component hedge recorded accumulated comprehensive income loss unrealized gain loss hedging instrument see note hedged forecasted transactions occur hedges dedesignated unrealized gains losses reclassified product sales time substantially values reported accumulated comprehensive income december reclassified product sales within months december net unrealized gains losses million million respectively open foreign currency exchange contracts net losses cash flow hedges recorded product sales decreased product sales million million million respectively residual changes fair value hedging instruments including resulting cancellation dedesignation hedge contracts ineffectiveness recognized immediately interest income net impact hedge ineffectiveness significant consolidated statements operations notional amounts foreign currency exchange forward option contracts outstanding billion december billion december hedge asset liability fair value million million december respectively acquisitions navitas assets llc may executed asset purchase agreement navitas assets llc navitas acquire assets related cicletanine business acquired exclusive rights regulatory data filings development cicletanine monotherapy pah indications united states plan evaluate cicletanine potential treatment pah aggregate purchase price acquisition million consisted primarily cash paid addition navitas entitled potential additional purchase consideration including payments contingent future achievement certain development regulatory milestones amounts recorded related contingencies resolved purchase price allocated iprd represents purchased iprd program cicletanine yet reached technological feasibility alternative future uses acquisition date therefore expensed upon acquisition within consolidated statement operations nycomed limited september completed acquisition nycomed limited nycomed whollyowned irish subsidiary germanybased pharmaceutical company nycomed gmbh nycomed facility located cork ireland conducted manufacturing tableting operations nycomed gmbh transferred certain manufacturing operations dublin ireland area site facility utilize site primarily solid dose tablet manufacturing existing future products well product packaging nycomed acquisition accounted business combination accordance sfas business combinations sfas results operations nycomed since completion acquisition september included consolidated statements operations table contents gilead sciences inc notes consolidated financial statementscontinued aggregate purchase price nycomeds common stock million consisted cash paid closing million estimated direct transaction costs million employeerelated severance costs million employeerelated severance costs capitalized part purchase price established workforce reduction plan part acquisition transaction accordance eitf issue recognition liabilities connection purchase business combination eitf costs fully paid purchase price allocated primarily property plant equipment million remaining balance allocated net working capital september connection transfer certain manufacturing operations dublin ireland area site cork facility finalized personnel plan respect dublin employees met criteria recognizing expensing onetime termination benefits sfas accounting costs associated exit disposal activities fourth quarter estimated termination benefits totaled approximately million myogen inc november completed acquisition outstanding shares common stock myogen cash tender offer terms agreement plan merger entered october myogen publiclyheld biopharmaceutical company based westminster colorado focused discovery development commercialization small molecule therapeutics treatment cardiovascular disorders myogen two product candidates late stage clinical development ambrisentan treatment patients pah darusentan treatment patients resistant hypertension acquisition provided us opportunity expand cardiovascular therapeutic area myogen acquisition accounted business combination accordance sfas results operations myogen since november included consolidated statement operations aggregate purchase price myogens common stock billion consisted cash paid prior closing billion fair value vested stock options assumed million direct transaction costs million consisted primarily investment banking fees employee related severance costs million reduction income taxes payable million resulted primarily exercise stock options assumed myogen vested acquisition date reduction income taxes payable resulted decrease aggregate purchase price employeerelated severance costs capitalized part purchase price established workforce reduction plan part acquisition transaction accordance eitf costs fully paid accordance merger agreement entered myogen conversion value stock option assumed determined based exercise price option purchase shares common stock myogen average closing price common stock five consecutive trading days immediately preceding including tender offer acceptance date november per share estimated fair value stock options assumed determined using average price per share approximated price would resulted averaging closing price common stock two trading days two trading days acceptance date accordance eitf issue determination measurement date market price acquirer securities issued purchase business combination fair value stock options assumed calculated using blackscholes valuation model following assumptions expected term ranging years riskfree interest rate ranging expected volatility ranging dividend yield fair value converted gilead stock options exceed fair value myogen stock options immediately prior exchange table contents gilead sciences inc notes consolidated financial statementscontinued approximately million million converted shares subject outstanding myogen stock options fully vested acquisition date estimated fair value vested options million included purchase price estimated fair value unvested options million included purchase price recognized stockbased compensation expense remaining future vesting period options following table summarizes purchase price allocation november thousands cash cash equivalents shortterm marketable securities accounts receivable net prepaid expenses assets accounts payable deferred revenue liabilities net tangible assets deferred tax assets purchased inprocess research development goodwill total purchase price million deferred revenue reflected fair value deferred revenue legal performance obligations accordance eitf issue accounting business combination deferred revenue acquiree million deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations concluded based standard set forth sfas likely realize benefits deferred tax assets elected treat myogen acquisition asset acquisition california state tax purposes purchased iprd goodwill resulting acquisition deductible california state income tax purposes although amounts deductible federal income tax purposes estimated fair value purchased iprd billion determined management purchased iprd represents myogens incomplete rd programs yet reached technological feasibility alternative future uses acquisition date therefore expensed upon acquisition within consolidated statement operations summary programs acquisition date updated subsequent changes status development follows table contents gilead sciences inc notes consolidated financial statementscontinued estimated acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide phase clinical trials completed prior acquisition date filed propanoic acidclass endothelin receptor nda fda december june fda antagonist era treatment pah approved letairis treatment pah united states additionally march european medicines agency emea validated marketing authorization application ambrisentan treatment pah filed collaboration partner glaxosmithkline inc gsk april european commission granted gsk marketing authorization ambrisentan treatment pah marketed name volibris gsk darusentan orally active etaselective era phase clinical development acquisition date date treatment resistant hypertension filing estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated fair value purchased iprd using present value discount rate based estimated internal rate return myogens operations comparable estimated weightedaverage cost capital companies myogens profile represents rate market participants would use value purchased iprd compensated differing phases development ambrisentan darusentan probabilityadjusting estimation expected future cash flows associated program determined time present value expected future cash flows using discount rate projected cash flows ambrisentan darusentan programs based key assumptions estimates revenues operating profits related programs considering stages development time resources needed complete development approval related product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets remaining efforts completing darusentan iprd program consist primarily clinical trials cost length success extremely difficult predict obtaining necessary regulatory approvals numerous risks uncertainties exist could prevent completion development including possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain darusentan treatment resistant hypertension approved united states countries outside united states whether marketing approvals significant limitations use future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections darusentan may never successfully commercialized result may make strategic decision discontinue development darusentan example believe commercialization difficult relative opportunities pipeline program completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely table contents gilead sciences inc notes consolidated financial statementscontinued successful completion project materialize estimated reasons among others actual results may vary significantly estimated results excess purchase price fair value amounts assigned assets acquired liabilities assumed million represented goodwill amount resulting myogen acquisition recorded goodwill noncurrent asset consolidated balance sheet acquisition date accordance sfas goodwill tested impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount raylo chemicals inc november completed acquisition outstanding shares common stock raylo chemicals inc raylo whollyowned subsidiary germanybased specialty chemicals company degussa ag located edmonton canada raylos operations encompassed custom manufacturing active pharmaceutical ingredients advanced intermediates pharmaceutical biopharmaceutical industries utilize raylo site process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational commercial products chemical development activities improve existing commercial manufacturing processes raylo acquisition accounted business combination accordance sfas results operations raylo since november included consolidated statements operations aggregate purchase price raylos common stock million consisted cash paid prior closing million direct transaction costs million employeerelated severance costs million employeerelated severance costs capitalized part purchase price established workforce reduction plan part acquisition transaction accordance eitf costs fully paid following table summarizes purchase price allocation november thousands net tangible assets gmp qualification intangible asset goodwill total purchase price million net tangible assets included million cash million property plant equipment million tangible assets less assumed liabilities million estimated fair value million associated good manufacturing practices gmp qualification raylos facilities determined management value recorded intangible asset amortized straightline basis three years estimated useful life asset determined management based amount time would derive benefit make substantial upgrades revisions acquired manufacturing practices december accumulated amortization asset million million respectively amortization expense recognized million million million respectively estimated amortization expense recognized approximately million asset expected fully amortized november excess purchase price fair value amounts assigned assets acquired liabilities assumed million represented goodwill resulting raylo acquisition recorded table contents gilead sciences inc notes consolidated financial statementscontinued goodwill noncurrent asset consolidated balance sheet acquisition date elected treat raylo acquisition asset acquisition federal california state tax purposes goodwill resulting acquisition deductible federal california state income tax purposes prior acquisition raylo one longstanding contract manufacturers determined accordance eitf issue accounting preexisting relationships parties business combination settlement preexisting relationship part business combination value needed assigned preexisting relationship purchase price allocation summarized raylos assets acquisition date included million trade receivables us eliminated consolidated balance sheet upon completion acquisition corus pharma inc august completed acquisition corus privatelyheld biopharmaceutical company based seattle washington corus development stage company focused development commercialization novel drugs respiratory infectious diseases corus one lead product candidate late stage clinical trials two early stage product candidates acquisition provided us opportunity expand respiratory therapeutic area well augment pipeline corus acquisition accounted acquisition assets rather business combination accordance criteria outlined eitf issue determining whether nonmonetary transaction involves receipt productive assets business sfas corus considered development stage company commenced planned principal operations additionally lacked necessary elements business including completed product therefore ability access customers results operations corus since august included consolidated statements operations april purchased million coruss series c preferred stock represented approximately coruss voting equity interests time conjunction purchase series c preferred stock also entered agreement plan merger option acquire merger remaining outstanding shares corus july announced agreed exercise option concurrently entered agreement novartis vaccines diagnostics inc novartis whereby novartis agreed dismiss litigation corus payment made us novartis since claims made novartis directly implicated coruss right develop commercialize products settling novartis deemed appropriate allow completion acquisition ensure claims novartis could impede ability develop commercialize coruss product candidates without settlement results ongoing trial time settlement would uncertain sustained period following closing due legal appeals potential proceedings upon completion acquisition included investment coruss series c preferred stock payment novartis part acquisition purchase price aggregate purchase price acquired shares million consisted cash paid prior closing million fair value vested stock options assumed million direct transaction costs million employeerelated severance costs million addition holdback amount million payable corus stockholders us one year closing merger except extent utilized pay claims made us within one year assessed probable would pay holdback amount recorded amount accrued liabilities consolidated balance sheet acquisition date paid holdback amount million august employeerelated severance costs capitalized part purchase price established workforce reduction plan part acquisition transaction costs fully paid table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes purchase price allocation august thousands net tangible assets assembled workforce net deferred tax assets purchased inprocess research development total purchase price million net tangible assets included million cash million marketable securities million tangible assets less assumed liabilities million million value assigned assembled workforce amortized three years estimated useful life asset million net deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations concluded based standard set forth sfas likely realize benefits deferred tax assets elected treat corus acquisition asset acquisition california state tax purposes purchased iprd resulting acquisition deductible california state income tax purposes although amount deductible federal income tax purposes estimated fair value purchased iprd assembled workforce determined management estimated fair value purchased iprd greater purchase price paid therefore amount allocated purchased iprd consisted net amount remaining allocating purchase price net tangible assets assembled workforce net deferred tax assets purchased iprd represented coruss incomplete rd program yet reached technological feasibility alternative future use acquisition date therefore expensed upon acquisition within consolidated statement operations summary program acquisition date updated subsequent changes status development follows estimated acquisition date fair value program description status development millions aztreonam inhalation aztreonam formulation phase clinical trials acquisition date filed nda solution inhalation used fda november september received complete treatment cystic gramnegative bacteria response letter fda informing us fda approve fibrosis cf cause lung infections patients nda aztreonam inhalation solution treatment cf cf current form requesting conduct additional phase clinical study november filed request formal dispute resolution fda february response appeal fda notified us reiterating position need conduct another clinical study aztreonam inhalation solution resubmit nda also submitted marketing authorization application european union received notice acceptance priority review health canada approval canada still awaiting responses respective regulatory bodies table contents gilead sciences inc notes consolidated financial statementscontinued estimated fair value purchased iprd determined using income approach discounts expected future cash flows present value estimated fair value purchased iprd using present value discount rate based estimated internal rate return coruss operations comparable estimated weightedaverage cost capital companies coruss profile represents rate market participants would use value purchased iprd projected cash flows aztreonam inhalation solution program based key assumptions estimates revenues operating profits related program considering stage development time resources needed complete development approval related product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets coruss two early stage candidates included valuation purchased iprd early stage projects identifiable revenues expenses associated remaining efforts completing coruss iprd program consist primarily clinical trials cost length success extremely difficult predict numerous risks uncertainties exist could prevent completion development including possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals certain aztreonam inhalation solution treatment cf approved united states countries outside united states whether marketing approvals significant limitations use aztreonam inhalation solution treatment cf may never successfully commercialized result may make strategic decision discontinue development aztreonam inhalation solution treatment cf example believe commercialization difficult relative opportunities pipeline program completed timely basis prospects future revenue growth may adversely impacted assurance given underlying assumptions used forecast cash flows timely successful completion project materialize estimated reasons among others actual results may vary significantly estimated results acquisition real estate october signed purchase sale agreement purchase office building approximately acres land located foster city california aggregate purchase price approximately million made initial refundable deposit million escrow october included current assets december january remaining balance million paid escrow upon closing transaction part closing purchase sale agreement amended allow holdback escrow million purchase price released depending outcome certain requirements mutually agreed closing asset disposal march received local city approval proceed demolition two buildings foster city california begin construction new facility included charge associated writeoff buildings equal aggregate net book value million sga expenses table contents gilead sciences inc notes consolidated financial statementscontinued availableforsale securities following summary availableforsale securities recorded cash equivalents marketable securities consolidated balance sheets estimated fair values availableforsale securities generally based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december debt securities us treasury securities us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities debt securities total debt securities equity securities total december debt securities us treasury securities us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities debt securities total debt securities equity securities total december debt securities consisted primarily money market funds auction rate securities following table presents classification availableforsale securities consolidated balance sheets thousands december cash cash equivalents shortterm marketable securities longterm marketable securities total december portfolio availableforsale debt securities comprised billion securities contractual maturity less one year billion securities contractual table contents gilead sciences inc notes consolidated financial statementscontinued maturity greater one year less five years million securities contractual maturity greater five years less ten years million securities contractual maturity greater ten years securities contractual maturity greater ten years comprised asset backed securities included mortgagebacked securities auction rate securities following table presents certain information related sales marketable securities thousands year ended december gross realized gains sales gross realized losses sales december following availableforsale debt securities continuous unrealized loss position deemed otherthantemporarily impaired thousands less months months greater gross gross unrealized estimated unrealized estimated losses fair value losses fair value december us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities debt securities total december us treasury securities us government sponsored entity debt securities corporate debt securities assetbacked securities municipal debt securities total december gross unrealized losses primarily caused increase yieldtomaturity underlying securities approximately total number investments unrealized loss positions case auction rate securities gross unrealized losses caused higher discount rate used valuation securities compared coupon rates securities significant facts circumstances arisen indicate deterioration creditworthiness issuers securities based review securities including assessment duration severity related unrealized losses ability intent hold investments maturity otherthan temporary impairments securities december result review investments otherthantemporary impairment recorded total charge million interest income net writedown cost basis investments common stock achillion pharmaceuticals inc achillion see note assetbacked commercial paper abcp structured investment vehicle million million respectively december table contents gilead sciences inc notes consolidated financial statementscontinued recorded total charge million interest income net writedown cost basis investments common stock achillion assetbacked commercial paper abcp structured investment vehicle million million respectively otherthantemporary impairments achillion based quoted market price achillion common stock september december compared cost basis assessment based primarily observation quoted market value investment less carrying value three consecutive quarters otherthantemporary impairment abcp based various market factors including estimated fair value underlying collateral abcp december investment common stock achillion abcp million million respectively recorded longterm marketable securities shortterm marketable securities respectively consolidated balance sheet inventories inventories summarized follows thousands december raw materials work process finished goods total inventories december joint ventures formed gilead bms see note included consolidated financial statements held million million inventory respectively efavirenz active pharmaceutical ingredient purchased bms bmss estimated net selling price sustiva established gilead access program pursuant make truvada viread available substantially reduced prices countries developing world based regular evaluation forecasted sales pricing inventory shelf life concluded would fully recover full carrying value associated inventory truvada viread gilead access program result recorded charge million cost goods sold write inventory estimated net realizable value table contents gilead sciences inc notes consolidated financial statementscontinued property plant equipment property plant equipment summarized follows thousands december property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress subtotal less accumulated depreciation amortization including relating capitalized leased equipment respectively subtotal land total collaborative arrangements result entering strategic collaborations time time may hold investments nonpublic companies review interests investee companies consolidation andor appropriate disclosure provisions fin r december determined certain investee companies variable interest entities however respect joint ventures bms primary beneficiary therefore consolidate investees bristolmyers squibb company north america december entered collaboration bms united states develop commercialize single tablet regimen containing truvada bmss sustiva collaboration structured joint venture operates limited liability company consolidate named bristolmyers squibb gilead sciences llc ownership interests joint venture thus sharing product revenue costs reflect respective economic interests bms us based proportions net selling price atripla attributable sustiva truvada since net selling price truvada may change time relative net selling price sustiva bms respective economic interests joint venture may vary annually share marketing sales efforts bms parties obligated provide equivalent sales force efforts minimum number years responsible accounting financial reporting tax reporting product distribution joint venture parties provide respective bulk active pharmaceutical ingredients joint venture approximate market values july joint venture received approval fda sell atripla united states september bms amended joint ventures collaboration agreement allow joint venture sell atripla canada october joint venture received approval health canada sell atripla canada december joint venture held efavirenz active pharmaceutical ingredient purchased bms table contents gilead sciences inc notes consolidated financial statementscontinued bmss estimated net selling price sustiva us market amounts included inventories consolidated balance sheets december total assets held joint venture billion million respectively consisted cash cash equivalents accounts receivable including intercompany receivables gilead inventories prepaid assets december total liabilities held joint venture million million respectively consisted accounts payable including intercompany payables gilead accrued expenses although primary beneficiary joint venture legal structure joint venture limits recourse creditors general credit assets europe december gilead sciences limited gsl one whollyowned subsidiaries ireland bms entered collaboration arrangement commercialize distribute atripla european union norway iceland switzerland liechtenstein european territory parties formed limited liability company consolidate manufacture atripla distribution europe using efavirenz purchased bms bmss estimated net selling price efavirenz european territory responsible product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories copromote atripla bms also responsible accounting financial reporting tax reporting collaboration december european commission approved atripla sale european union december efavirenz purchased bms bmss estimated net selling price efavirenz european territory included inventories consolidated balance sheets parties formed bristolmyers squibb gilead sciences limited limited liability company hold marketing authorization atripla europe primary responsibility regulatory activities share marketing sales efforts bms major market countries parties agreed provide equivalent sales force efforts revenue cost sharing based relative ratio truvada sustivas respective net selling prices pari gmbh result acquisition corus august assumed rights february development agreement corus pari gmbh pari development aztreonam inhalation solution development inhalation delivery device drug candidate terms agreement obligated pay pari services rendered subject achievement specific milestones obligated pay certain milestone payments pari addition make royalty payments based net sales aztreonam inhalation solution approved commercialization agreement also provided us right reduce royalty rate payable pari november paid pari million reduce royalty rate agreement aztreonam inhalation solution yet approved commercialization recorded payment rd expenses consolidated statement operations april pursuant february development agreement entered commercialization agreement pari provides supply manufacture inhalation delivery device accessories use aztreonam inhalation solution terms agreement obligated pay royalties future net sales products pursuant development agreement table contents gilead sciences inc notes consolidated financial statementscontinued lg life sciences ltd november entered license agreement lg life sciences ltd lgls develop commercialize certain caspase inhibitors treatment fibrotic diseases agreement granted us commercialization rights lglss caspase inhibitors including lb gs terms agreement license worldwide exception korea china india lgls retained rights lgls also retains right develop commercialize caspase inhibitors ophthalmic topical uses worldwide accordance terms agreement paid million upfront license fee recorded rd expenses consolidated statement operations future alternative use technology agreement also obligated us fund collaborative research program two years identify potential caspase inhibitor drug candidates addition obligated make additional milestone payments million upon achievement certain development regulatory commercial objectives also obligated pay royalties future net sales products developed approved relation collaboration parion sciences inc august entered research collaboration license agreement parion sciences inc parion research develop commercialize certain epithelial sodium channel inhibitors treatment pulmonary diseases agreement granted us worldwide commercialization rights p gs epithelial sodium channel enac inhibitor discovered parion treatment pulmonary diseases including cf chronic obstructive pulmonary disease noncf bronchiectasis accordance terms agreement paid million upfront license fee recorded rd expenses consolidated statement operations future alternative use technology made million investment parion form convertible debt recorded noncurrent assets consolidated balance sheet collaboration agreement lead development commercialization activities provide funding full time equivalent employees certain research activities addition obligated make additional payments upon achievement certain milestones pay royalties future net sales products developed approved relation collaboration roche september entered development license agreement agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales turn subject reduction certain defined manufacturing costs november entered first amendment supplement agreement roche amended agreement provided formation joint manufacturing committee review roches manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis case consisting representatives roche us amended agreement also option provide specialized sales force supplement roches marketing efforts united states tamiflu royalties payable us net sales tamiflu sold roche remain amended agreement follows first million worldwide net sales given calendar year b next million worldwide net sales calendar year c table contents gilead sciences inc notes consolidated financial statementscontinued worldwide net sales excess million calendar year amended agreement revised provision agreement relating calculation royalty payments given calendar quarter roche pay royalties based actual royalty rates applicable quarter addition amended agreement royalties payable roche us longer subject cost goods sold adjustment provided agreement recorded total million million million tamiflu royalties respectively japan tobacco inc march japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor known gs countries world excluding japan japan tobacco retained rights terms agreement incurred upfront license fee million included rd expenses future alternative use technology march recorded million rd expenses related milestone incurred result dosing first patient phase clinical study july recorded million rd expenses related milestone paid related dosing first patient phase clinical study obligated make additional payments upon achievement milestones well pay royalties future product sales arising collaboration achillion pharmaceuticals inc november achillion granted us worldwide rights research development commercialization certain small molecule hepatitis c virus hcv replication inhibitors involving hcv protease treatment hepatitis c collaboration achillion obligated continue development inhibitor compounds according mutually agreed upon development plan completion proof concept clinical study hcv infected patients costs incurred achieve proof concept would shared equally achillion us following proof concept study obligated assume full responsibilities incur costs associated development commercialization compounds warranting development achillion option participate us commercialization efforts future products arising collaboration conjunction signing collaboration paid million upfront license fee recorded rd expenses future alternative use licensed technology additionally invested million achillions convertible preferred stock agreed make payments achillion upon achievement certain milestones outlined agreement well pay royalties future net sales products arising collaboration october achillion completed initial public offering convertible preferred stock converted shares achillion common stock recorded writedown million million respectively part review otherthantemporary impairment since quoted market price achillions common stock less cost basis three consecutive quarters glaxosmithkline inc april granted gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territories agreement retained rights hepsera united states canada europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment chronic hepatitis b territories significant include china japan south korea taiwan gsk full responsibility development commercialization hepsera territories terms agreement received table contents gilead sciences inc notes consolidated financial statementscontinued upfront license payment million received aggregate million milestone payments related commercial approvals hepsera various countries received aggregate million milestone payments gsk achievement gsk four consecutive quarters hepsera gross sales exceeding million achievement certain drug status china upfront license fee milestone payments recorded deferred revenue total million million million amortized contract revenue respectively million balance deferred revenue december expected amortized contract revenue period supply hepsera gsk terms agreement gsk also required pay us royalties net sales gsk generates sales hepsera epivir hbvzeffix gsks hepatitis product gsk territories recorded million million million royalty revenues respectively result acquisition myogen november assumed rights march license distribution supply agreements myogen gsk terms license agreement gsk received exclusive sublicense rights ambrisentan certain hypertensive conditions territories outside united states received upfront payment million subject achievement specific milestones eligible receive total additional milestone payments million addition receive stepped royalties based net sales ambrisentan gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses ambrisentan gsk territories term license agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals ambrisentan united states canada european economic area party may conduct additional development activities territories expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development received milestone payment million gsk validation emea marketing authorization application ambrisentan treatment pah received million milestone payment related european commission marketing authorization approval ambrisentan treatment pah marketed name volibris gsk milestone upfront license payments recorded deferred revenue amortized contract revenue remaining period performance obligations agreement approximately seven years amortized million million million contract revenue respectively longterm obligations convertible senior notes april issued million principal amount convertible senior notes due notes million principal amount convertible senior notes due notes collectively notes private placement pursuant rule securities act amended notes notes issued par bear interest rates respectively debt issuance costs million connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual terms notes aggregate principal amount notes sold reflects full exercise initial purchasers option purchase additional notes cover allotments notes may convertible common stock based initial conversion rate shares per principal amount notes represents initial conversion price approximately per share notes may convertible common stock based initial conversion rate shares per principal amount notes represents initial conversion price approximately per share notes may converted subject adjustment following circumstances calendar quarter beginning table contents gilead sciences inc notes consolidated financial statementscontinued september closing price common stock least trading days last consecutive trading day period previous quarter applicable conversion price per share make specified distributions holders common stock specified corporate transactions occur last month prior maturity applicable notes upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value note conversion value exceeds may also deliver option cash common stock combination cash common stock conversion value excess notes converted connection change control may required provide make whole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount notes plus accrued unpaid interest thereon december fair values notes notes approximately million million respectively based quoted market values concurrent issuance notes purchased convertible note hedges private transactions cost million cover subject customary antidilution adjustments million shares common stock strike prices correspond initial conversion prices notes market value per share common stock time conversion notes strike price applicable convertible note hedges entitled receive counterparties transactions cash shares common stock combination cash common stock option excess market price common stock strike price convertible note hedges convertible note hedges terminate upon maturity related notes none related notes remain outstanding due conversion otherwise also sold warrants acquire million shares common stock subject customary antidilution adjustments private transactions received net proceeds million market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices maximum number shares common stock could issued us choose net share settle warrants million shares underlying share amount reserved potential future issuance warrants strike prices per share warrants expiring per share warrants expiring exercisable respective expiration dates taken together convertible note hedges warrants intended reduce potential dilution upon future conversions notes effectively increasing initial conversion price per share notes per share notes net cost million convertible note hedges warrant transactions recorded stockholders equity choice settling convertible note hedges warrants cash shares stock contracts meet applicable criteria equity classification outlined eitf issue accounting derivative financial instruments indexed potentially settled companys stock eitf cost convertible note hedges net proceeds sale warrants classified stockholders equity addition contracts classified stockholders equity indexed common stock accounted derivatives sfas also recorded deferred tax asset million apic effect future tax benefits related convertible note hedges accordance sfas eitf issue income tax consequences issuing convertible debt beneficial conversion feature contemporaneously closing sale notes portion net proceeds notes issuance proceeds warrant transactions used repurchase million shares common stock million stock repurchase program table contents gilead sciences inc notes consolidated financial statementscontinued terms notes agreements require us comply certain covenants december compliance covenants credit facilities december entered agreement syndicate banks five year million senior credit facility million facility consisted uncollateralized million term loan entered gilead biopharmaceutics ireland corporation gbic one whollyowned irish subsidiaries uncollateralized million revolving credit facility entered us parent company gilead sciences inc proceeds term loan used gbic december facilitate cash dividend distribution million us parent company part repatriation qualified foreign earnings provisions american jobs creation act ajca year ended december repaid million represented remaining amounts due term loan time term loan terminated terms revolving credit facility entered december interest accrued payable rate libor plus tiered contractual rate basis points payable quarterly arrears us parent company could prepay outstanding borrowings together accrued interest prepaid principal time whole part without penalty premium outstanding interest principal december would payable demand capacity revolving credit facility would increase maximum million term loan repaid ability irrevocably cancel unutilized portion revolving credit facility whole part proceeds obtained revolving credit facility expected used working capital capital expenditures general corporate purposes including issuance letters credit million one whollyowned subsidiaries guarantor december entered amended restated credit agreement superseded existing revolving credit agreement syndicate banks increase credit facility billion amended restated credit agreement also includes subfacility swingline loans letters credit entered gbic us parent company terms amended restated credit agreement may borrow initially aggregate billion revolving credit loans loans amended restated credit agreement bear interest either libor plus margin ranging basis points basis points ii base rate defined amended restated credit agreement prepay outstanding borrowings time whole part without penalty premium outstanding interest principal would due payable december connection amended restated credit agreement us parent company entered agreement guaranteeing obligations gbic amended restated credit agreement expect use proceeds loans amended restated credit agreement working capital requirements general corporate purposes december million letters credit outstanding amended restated credit agreement required comply certain covenants amended restated credit agreement december compliance covenants commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities lease facilities foster city san dimas california durham north carolina boulder westminster colorado seattle washington dublin area ireland london area united kingdom also table contents gilead sciences inc notes consolidated financial statementscontinued operating leases sales marketing administrative facilities europe canada australia leases expire various dates leases ireland united kingdom years respectively rent subject increase fifth anniversary respective commencement dates many facility leases options renew equipment leases include three corporate aircraft varying terms renewal options upon expiration lease terms lease expense operating leases totaled approximately million million million aggregate noncancelable future minimum rental payments operating leases years ending december follows thousands thereafter legal proceedings may united states district court northern district california executed orders dismissing entirety prejudice fourth consolidated amended complaint associated purported class action lawsuit us chief executive officer chief operating officer former executive vice president operations executive vice president research development chief scientific officer senior vice president manufacturing senior vice president research alleging defendants violated federal securities laws specifically sections b securities exchange act amended rule b promulgated sec making certain alleged false misleading statements august united states court appeals ninth circuit reversed district courts decision remanded case district court february filed petition writ certiorari supreme court united states requesting court review judgment court appeals supreme court reviews petition case continues district court february filed motion dismiss fourth consolidated amended complaint possible predict outcome case amounts accrued related outcome case november received subpoena united states attorneys office san francisco requesting documents regarding marketing medical education programs truvada viread emtriva cooperating continue cooperate related governmental inquiry possible predict outcome inquiry amounts accrued related outcome inquiry also party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments august result review terms existing corporate aircraft leases upon consideration various alternatives available us upon expiration entered agreements table contents gilead sciences inc notes consolidated financial statementscontinued purchase three aircraft constructed delivery aggregate purchase price purchase agreements million december made deposits totaling million recorded noncurrent assets consolidated balance sheet future deposits due terms purchase agreements follows million million million million million option terminate purchase agreements subject maximum payment fully equipped price aircraft normal course business enter various firm purchase commitments related active pharmaceutical ingredients certain inventory related items december commitments next five years million million million million million amounts related active pharmaceutical ingredients represent minimum purchase requirements actual payments purchases related active pharmaceutical ingredients billion million million years ended december respectively stockholders equity stock repurchase programs march board directors board authorized program repurchase common stock amount billion two year period open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated stock repurchase transactions similar arrangements april repurchased retired shares common stock per share aggregate purchase price million may june repurchased retired aggregate shares common stock average purchase price per share aggregate purchase price million stock repurchase program expired march october board authorized new program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated stock repurchase transactions similar arrangements repurchase plan expires december repurchased retired shares common stock per share aggregate million billion stock repurchase program february entered accelerated share repurchase agreement financial institution repurchase million common stock accelerated basis terms accelerated share repurchase agreement paid million financial institution settle initial purchase transaction received shares common stock price per share june upon maturity agreement accordance share delivery provisions agreement received additional shares common stock based average daily volume weighted average prices common stock specified period less predetermined discount per share result final purchase price common stock accelerated share repurchase per share accordance eitf issue accounting accelerated share repurchase program accounted accelerated share repurchase two separate transactions shares common stock acquired treasury stock transaction recorded transaction date b forward contract indexed common stock accounted shares received repurchase common stock retired shares immediately net income per share purposes additional table contents gilead sciences inc notes consolidated financial statementscontinued shares received upon maturity contract june also recorded stockholders equity determined forward contract indexed common stock met applicable criteria equity classification accordance eitf therefore contract accounted derivative sfas october entered accelerated share repurchase agreement financial institution repurchase million common stock accelerated basis terms accelerated share repurchase agreement paid million financial institution settle initial purchase transaction received shares common stock price per share april subject extension certain circumstances well maximum minimum share delivery provisions agreement may receive additional shares financial institution depending average daily volume weightedaverage prices common stock specified period less predetermined discount per share making initial payment million obligated deliver cash shares financial institution except certain limited circumstances case method delivery cash shares common stock would discretion accounting accelerated share repurchase consistent previous accelerated share repurchase addition common stock repurchased two accelerated share repurchase transactions repurchased retired shares common stock average purchase price per share aggregate purchase price million open market transactions december remaining authorized amount stock repurchases may made billion stock repurchase program expires december million use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated apic based estimated average sales price per issued share excess amounts charged retained earnings result stock repurchases reduced common stock apic aggregate million charged million retained earnings result stock repurchases reduced common stock apic aggregate million charged billion retained earnings preferred stock shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series designated shares series junior participating preferred stock potential issuance november rights agreement bny mellon investor services llc formerly known chasemellon shareholder services llc amended rights plan preferred stock outstanding december rights plan rights plan provides distribution preferred stock purchase right dividend share common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed table contents gilead sciences inc notes consolidated financial statementscontinued board whole part price per purchase right purchase rights voting privileges attached automatically trade common stock october october may board approved amendments rights plan first amendment provided among things increase exercise price right plan extension term plan november october second amendment provides among things increase exercise price right plan extension term rights plan october third amendment clarifying amendment entered connection increase designated number shares series junior participating preferred stock potential issuance rights plan may stock option plans may stockholders approved adopted equity incentive plan plan stock options nexstar pharmaceuticals inc nexstar triangle pharmaceuticals inc triangle corus myogen stock option plans assumed result acquisitions nexstar triangle corus myogen converted options purchase common stock effective closing respective acquisitions plan broad based incentive plan allows awards granted employees directors consultants plan provides option grants designated either nonqualified incentive stock options prior january granted nonqualified incentive stock options stock options granted january nonqualified stock options plan employee stock options generally vest five years exercisable period exceed contractual term ten years date stock options issued granted prices less fair value common stock grant date stock option exercises settled newly issued common stock plans previously authorized available pool shares may stockholders approved increase additional shares common stock available issuance plan december total shares common stock authorized grant shares remain available future grant plan following table summarizes activity stock option plans option grants presented table exercise prices less fair value underlying common stock grant date shares thousands year ended december weighted weighted weighted average average average shares exercise price shares exercise price shares exercise price outstanding beginning year granted assumed forfeited exercised outstanding end year exercisable end year weightedaverage grant date fair value options granted year table contents gilead sciences inc notes consolidated financial statementscontinued total intrinsic value options exercised years ended december million million million respectively total fair value stock options vested years ended december million million million respectively december number options outstanding expected vest net estimated future option forfeitures accordance provisions sfas r weightedaverage exercise price aggregate intrinsic value million weightedaverage remaining contractual life years aggregate intrinsic value stock options outstanding stock options exercisable december billion billion respectively december weightedaverage remaining contractual life options outstanding stock options exercisable years respectively following summary stock options outstanding stock options exercisable december options thousands options outstanding options exercisable weighted weighted options average options average range exercise prices outstanding exercise price exercisable exercise price total december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years performance shares restricted stock awards january granted performance based share awards plan awards divided three tranches vesting performance measurement purposes subject achievement specified market performance goals relative predetermined peer group awards vest three year period actual number shares common stock ultimately issue calculated multiplying number performance shares payout percentage ranging performance shares vest committee subcommittee board determined achieved specified market performance goals fair value performance shares estimated grant date using monte carlo valuation methodology stockbased compensation performance shares recognized expense requisite service periods using straight line expense attribution approach reduced estimated forfeitures weightedaverage grant date fair value performance shares per share recognized million million stockbased compensation expense respectively relating performance shares january granted performance based share awards terms substantially similar awards granted except single three year performance measurement vesting period table contents gilead sciences inc notes consolidated financial statementscontinued weightedaverage grant date fair value performance shares per share recognized million stockbased compensation expense relating performance shares also granted restricted stock awards certain employees plan vesting certain awards subject achievement specified performance goals number restricted stock awards issued date significant december nonvested outstanding awards respectively employee stock purchase plan employee stock purchase plan amended espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair value common stock offering date purchase date two year lookback feature espp causes offering period reset fair value common stock purchase date less original offering date espp purchases employees settled newly issued common stock espps previously authorized available pool shares may stockholders approved amendments espp increase number shares authorized reserved issuance espp additional shares common stock extend term espp additional ten years january shares issued espp million total shares common stock reserved issuance espp shares available issuance espp december december million unrecognized compensation cost related espp expected recognized estimated weightedaverage period years stockbased compensation january adopted provisions sfas r requires sharebased payments employees directors including grants stock options recognized consolidated statements operations based fair values table summarizes stockbased compensation expense sfas r thousands except per share amounts year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense included net income loss stockbased compensation expense included net income loss per share basic diluted table contents gilead sciences inc notes consolidated financial statementscontinued years ended december capitalized million million million stockbased compensation costs inventory respectively stockbased compensation recognized expense requisite service periods consolidated statements operations using graded vesting expense attribution approach nonvested stock options granted prior adoption sfas r using straightline expense attribution approach stock options granted adoption sfas r stockbased compensation expense related stock options recognized adoption sfas r based awards ultimately expected vest gross expense reduced estimated forfeitures sfas r requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption sfas r pro forma information required sfas included forfeitures occurred result adoption sfas r recognize tax benefit stockbased compensation apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements operations rather apic valuation assumptions fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life connection adoption sfas r refined methodologies used derive valuation model assumptions used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted prior adoption sfas r calculated using multiple option approach fair value stock options granted beginning january calculated using single option approach prior adoption sfas r used historical stock price volatility connection blackscholes option valuation model connection adoption sfas r determined blend historical volatility along implied volatility traded options common stock better reflection expected volatility table contents gilead sciences inc notes consolidated financial statementscontinued expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weighted average expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts comprehensive income loss comprehensive income loss comprises net income loss certain changes stockholders equity excluded net income loss changes fair value outstanding effective cash flow hedges changes unrealized gains losses availableforsale securities changes cumulative foreign currency translation account comprehensive income loss years ended december included consolidated statement stockholders equity components comprehensive income loss shown net related taxes underlying assets liabilities held jurisdictions expected generate future tax benefit liability following reclassifications recorded connection net realized gains losses sales securities cash flow hedges previously included comprehensive income loss thousands year ended december net unrealized gain loss related availableforsale securities net tax benefit provision respectively net unrealized gain loss related cash flow hedges net tax benefit provision respectively reclassification adjustments net tax benefit respectively comprehensive income loss balance accumulated comprehensive income loss net taxes reported consolidated balance sheets consists following components thousands december net unrealized gain loss availableforsale securities net unrealized gain loss cash flow hedges cumulative foreign currency translation adjustment accumulated comprehensive income loss disclosures segments enterprise related information operate one business segment primarily focuses development commercialization human therapeutics life threatening diseases products included one segment major table contents gilead sciences inc notes consolidated financial statementscontinued products truvada atripla viread hepsera emtriva ambisome together accounted substantially total product sales years ended december similar economic characteristics including nature products production processes type customers distribution methods regulatory environment product sales consist following thousands year ended december antiviral products truvada atripla viread hepsera emtriva total antiviral products ambisome letairis total product sales following table summarizes total revenues external customers collaboration partners geographic region thousands product sales product related contract revenue attributed countries based shipto location royalty nonproduct related contract revenue attributed countries based location collaboration partner year ended december united states outside united states france spain united kingdom italy germany switzerland european countries countries total revenues outside united states total revenues december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes revenues customers individually accounted total revenues total revenues year ended december cardinal health inc mckesson corp amerisourcebergen corp f hoffmannla roche ltd amount less income taxes provision income taxes consists following thousands year ended december federal current deferred state current deferred foreign current deferred provision income taxes foreign pretax income million million million respectively cumulative unremitted foreign earnings considered permanently invested outside united states us taxes provided approximately billion billion december respectively residual us tax liability amounts remitted would approximately million million december respectively table contents gilead sciences inc notes consolidated financial statementscontinued difference provision income taxes amount computed applying us federal statutory income tax rate income loss provision income taxes follows thousands year ended december income loss provision income taxes tax federal statutory rate state taxes net federal benefit foreign earnings different rates purchased inprocess rd expenses research credits net unbenefited stock compensation provision income taxes deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows thousands december deferred tax assets convertible note hedges stockbased compensation capitalized intangibles reserves accruals currently deductible depreciation related research tax credit carryforwards net operating loss carryforwards net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance increased decreased million million million years ended december respectively concluded based standard set forth sfas likely realize benefit deferred tax assets related certain state net operating loss tax credit carryforwards december therefore released related valuation allowance resulting credit goodwill approximately million income tax benefit approximately million table contents gilead sciences inc notes consolidated financial statementscontinued december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards start expire utilized also federal tax credit carryforwards approximately million start expire utilized addition state net operating loss tax credit carryforwards approximately million million respectively state net operating loss tax credit carryforwards start expire respectively utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns many jurisdictions united states abroad us federal california income tax purposes statute limitations remains open years inception due utilization net operating losses relating prior years income tax returns audited federal state foreign tax authorities currently examination internal revenue service irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions december total federal state foreign unrecognized tax benefits million million respectively including interest million million respectively total unrecognized tax benefits december million million respectively recognized would reduce effective tax rate period recognition permitted provisions fin continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements operations reached agreement irs several issues related examinations federal income tax returns result reduced unrecognized tax benefits million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs around certain uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective taxing authorities table contents gilead sciences inc notes consolidated financial statementscontinued following rollforward total gross unrecognized tax benefit liabilities years ended december thousands december balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period deferred compensation plans maintain retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation subject irs plan limits make matching contributions gilead plan contributed employees contributions annual maximum match contributed employees first contributions annual maximum match respectively total matching contribution expense gilead plan million million million maintain deferred compensation plan directors key employees may defer compensation income tax purposes deferred compensation plan nonqualified deferred compensation plan subject qualification requirements section internal revenue code compensation deferred december subject requirements section internal revenue code plan officers senior grade level employees may contribute annual salaries annual bonus directors may contribute annual retainer fee amounts deferred participants deposited rabbi trust recorded noncurrent assets consolidated balance sheets beginning directors may also elect receive portion annual cash retainer phantom shares gives participant right receive amount equal value specified number shares specified period time payable shares common stock fractional shares paid cash established plan administrator december phantom shares outstanding participants elect one several distribution dates available plan receive deferred compensation payment table contents gilead sciences inc notes consolidated financial statementscontinued quarterly results operations unaudited following amounts thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales total costs expenses net income net income per sharebasic net income per sharediluted total revenues gross profit product sales total costs expenses net income net income per sharebasic net income per sharediluted second quarter recognized million charge purchased iprd associated acquisition assets navitas related cicletanine business table contents gilead sciences inc schedule ii valuation qualifying accounts balance additions balance beginning charged end period expense deductions period year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets allowances doubtful accounts sales returns cash discounts chargebacks valuation allowance deferred tax assets includes million million december respectively related acquisitions table contents